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ABSTRACT 
 The human body encounters a number of chemical exposures on a daily basis, 
which may have short- or long-term health implications. Previously it has been 
demonstrated that the entire respiratory tract of an individual reacts to exposures like 
tobacco smoke in a similar manner, and that common molecular changes can be 
measured in airway epithelium. I propose that cataloguing the exposure of airway 
epithelial cells to tobacco cigarette (TCIG) smoke and its constituents, electronic 
cigarette (ECIG) aerosol and other drugs and small molecules can significantly increase 
the understanding of chemical exposure and identify common gene expression 
alterations.  
 First, I determined the molecular impact of ECIG aerosol exposure on human 
airway epithelium in vitro, including alterations in genes related to xenobiotic 
metabolism, oxidative stress, and ciliated cells. These changes were generally less 
pronounced than the effects of TCIG exposure, and were more pronounced in ECIG 
products containing nicotine than those without nicotine. Furthermore, gene expression 
		 ix 
differences observed in vitro were concordant with differences observed in airway 
epithelium collected from ECIG users. Second, I examined the impact of TCIG exposure 
and TCIG constituents on premalignant airway cells, to better understand the progression 
or regression of precancerous lesions. These data could also identify the constituents of 
TCIGs and the precancerous mutations that increase the risk for malignancy. Third, in an 
effort to build a high-throughput methodology for chemical exposures, I exposed primary 
lung cell lines to small molecule therapeutics and identified lung-specific and lung cell-
type-specific effects of exposure, suggesting that profiling additional cell lines would 
further inform airway gene expression in response to exposure and that organ-specific 
exposure profiling may provide valuable insight into drug discovery for common 
diseases.  
 Overall, transcriptomic profiles from the airway epithelium reflect exposure to 
various inhaled and chemical perturbations. These gene expression profiles indicate 
common changes across a multitude of airway exposures as well as unique alterations 
specific to a given perturbation. Gene expression profiling can therefore be used to detail 
the potential response to a compendium of chemical exposures including those that are 
either well-established or potential risk factors for chronic lung diseases.  
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CHAPTER ONE: 
Introduction 
1.1 Understanding the impact of chemical exposures 
The human body encounters a number of chemical exposures on a daily basis. 
Many of these are benign, or benign at the small doses at which we are exposed to them, 
while others may have short-term or even long-term health implications. The likelihood 
of such an event depends on a number of factors including the dose, length, frequency, 
and mode of exposure. In particular the airway, from the nasal cavity to lung 
parenchyma, is greatly affected by exposure given its interface with the external 
environment and our constant inhalation 123,137. Previous exposure research has evaluated 
the effects of exposure to tobacco smoke, asbestos, radon, aerosolized food additives, all 
of which have been linked to lung disease 53,55,83. The largest body of this research 
focuses on exposure (whether direct or secondhand) to traditional tobacco cigarette 
(TCIG) smoke. Among the multiple components of tobacco smoke are over 60 
established carcinogens, including polycyclic aromatic hydrocarbons (PAHs) and N-
nitrosamines like 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 42,47,48. These 
compounds and the additional 4,000 identified chemicals of tobacco smoke are inhaled 
with each puff of cigarette smoke. Cigarette smoking significantly increases the risks of 
lung cancer, heart disease, chronic obstructive pulmonary disease (COPD), microbial 
infection, rheumatoid arthritis and other cancers of the mouth, larynx and bladder 
85,92,100,110,126. Additionally, secondhand smoke exposure, exposure to the side stream 
smoke off a smoldering cigarette, has been linked to impaired lung function, heart 
		
2 
disease, stroke and lung cancer, in adults 126,127. In children exposure to secondhand 
smoke is associated with an increased risk of sudden infant death syndrome (SIDS), 
asthma and bronchitis 99,126,127. As a result nearly 6 million deaths per year, worldwide, 
are attributable to TCIG use 21 and the cost of this disease burden is more than 300 billion 
dollars a year, including direct medical care and the costs of lost productivity due to 
premature death 21. Through exposure research these public health implications of TCIG 
use have become well known, and prevalence of tobacco use has decreased from 42 
percent of U.S. adults in 1965 to just 18 percent in 2012 126. However, more than 42 
million Americans still smoke despite clear disease warnings 126. As the compendium of 
research into TCIG exposure illustrates, understanding the impact of airway exposure is 
crucial to understanding the link between exposure and incident disease. 
 
1.2 Transcriptomics and its utility in airway exposure research 
  With the increasing availability and decreasing cost of sequencing and the 
immense amounts of DNA sequence information available, understanding the behavior 
and expression of an individual’s entire genome has become increasingly simple 68. This 
information, an evaluation of the expression of all genes and their functions, informs the 
area of research known as genomics. By cataloguing and understanding the compendium 
of genes within an individual’s genome, we can determine the significance of each gene 
and how groups of genes may work in concert to perform a particular function. These 
functions are typically carried out by protein, and in order to get this genetic information 
to the sites of protein synthesis, messenger RNA are transcribed from DNA. The process 
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by which this DNA information directs protein synthesis is called gene expression. 
Within the field of genomics, the study of the complete set of transcripts in a cell and 
their quantity, deemed transcriptomics, has emerged as an essential tool for 
understanding development and disease 132. Since total RNA acts as an intermediary 
between genes and protein, the set of RNA transcripts produced at any one time can 
provide an important look into cellular activity at that given moment. For this reason 
transcriptomics is especially useful for looking at how cells are affected by development, 
disease and exposure.  
 One challenge in exposure research is that long-term health impacts and disease, 
like those previously described, often arise from a combination of environmental 
exposures, on a particular genetic background 134,135. Understanding these gene-
environment interactions is essential to discerning the implications and pathways of 
exposure that result in imminent disease. Without the knowledge of these interactions the 
aforementioned deluge of sequencing data will be devoid of any public health 
implications. Transcriptomics provides the opportunity to further understand these gene-
environment interactions by allowing us to identify changes in gene expression (RNA 
transcription) following exposure, and determine their significance (Figure 1.1). 
Furthermore, transcriptomics provides “a more realistic view of exposure involving 
multiple exposures, at potentially low environmental concentrations, and multiple 
biologic response pathways” 133. Transcriptomic methods can help determine the 
biological pathways by which an exposure is exerting its effects, identify biomarkers of 
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exposure and inform susceptibility to disease 133. The utility of transcriptomics in 
exposure research, and airway research in particular, should not be understated.  
 
Figure 1.1: The utility of transcriptomics in understanding airway exposure and its impact on disease. Adapted 
from 38.  
 
1.3 Airway epithelium and the field of injury 
 The airspaces of the lung are lined by a pseuodostratified columnar epithelium 
which performs multiple functions essential to tissue homeostasis 96. This airway 
epithelium is comprised of multiple cell types including basal, ciliated, goblet, secretory 
and neuroendocrine cells 96.  Differences in the type and abundance of specialized 
epithelial cells at each location of the lung reflect regional needs for functions such as gas 
exchange and maintenance of an effective barrier to infectious agents and environmental 
insults 96,129. This dynamic phenotype and function of the airway epithelium can be 
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influenced by changing micro- and macro-environment conditions, an important property 
that allows the epithelium to withstand chronic stress 96. However, chronic stimuli may 
result in pathological remodeling, leading to changes in the barrier properties of the 
epithelium and interrupting mucociliary transport, all of which have the potential to 
compromise pulmonary mechanics and the important functions of the epithelium 96. 
Indeed, genomic profiles and functional pathways of the airway epithelium are altered in 
response to TCIG smoking, and these gene expression changes reflect host response to 
and damage from cigarette smoke 6,7,115. Therefore, the transcriptome of the airway 
epithelium can serve as an accurate and easily accessible tool for understanding the 
impact of chemical exposures.  
Previously, it has been demonstrated that the airway epithelium reacts to 
exposures like tobacco smoke in a similar manner, and that common aspects of this 
response can be measured in these cells 7,43,52,118. Therefore, by sampling the readily 
available normal airway epithelium we can use gene expression to understand this 
response. Additionally, similar to exposure, lung diseases also create a field of injury 
throughout the respiratory system and therefore we can use gene expression to identify 
both exposure-specific and disease-specific changes 14,43,105,112,114,117. This is particularly 
useful in understanding the mechanisms and biological pathways by which airway 
exposure can lead to lung disease. Specifically, it has been shown that pulmonary 
diseases like lung cancer and COPD induce transcriptomic changes in the histologically-
normal airway epithelial cells of smokers and that this gene expression can be used as a 
sensitive and specific indicator of incident lung cancer 105,114,117. Furthermore, research 
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has shown that exposure-reduction (i.e. smoking cessation) can mitigate exposure-
specific gene expression changes 7. Notably, it’s been shown that upon smoking 
cessation, while a large portion of smoking-induced gene expression changes revert to 
baseline levels, a number of changes persist in former smokers 7. In all, previous works 
suggest that airway epithelial gene expression can serve as a sensitive indicator of the 
physiological response to inhaled toxins and chemical exposures. 
 
1.4 Dissertation Aims 
 The following aims seek to characterize the physiologic effects of chemical 
exposures on human airway epithelium, utilizing gene expression profiling and 
transcriptomic analyses. These exposures include cigarette smoke and cigarette smoke 
constituents (major environmental risk factors for chronic lung disease) as well as 
electronic cigarette aerosol (an alternative and relatively recent tobacco product with 
unknown health effects) and a number of other established drugs and small molecules 
with known mechanisms of action and published therapeutic utility 62. We propose that 
cataloguing the exposure of airway epithelial cells to TCIG smoke, electronic cigarette 
(ECIG) aerosol, and other drugs and small molecules, can contribute significantly to the 
understanding of chemical exposures and identify common gene expression alterations. 
These studies will further provide insight into biological pathways altered by these 
exposures and inform future airway exposure research into their implications in lung 
disease. Finally, this catalogue will provide a resource for the community to better 
understand exposure-disease interactions, and identify potential lung therapeutics. 
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Aim 1: Examine the gene expression alterations in response to ECIG exposure on 
the airway epithelium in vitro and in vivo, to evaluate the safety of ECIG products. 
 ECIGs are electronic nicotine delivery systems that simulate tobacco smoking by 
delivering nicotine via an aerosol. While the gene expression alterations in response to 
tobacco smoke exposure are well established, the molecular effects of ECIG exposure on 
the airway epithelium are largely unknown. We have previously used airway gene-
expression profiles to gain insight into the response to smoking. In this project, I 
determine the molecular impact of ECIG aerosol exposure on human airway epithelium 
in vitro, including pathway alterations, and how responses to exposure vary based on 
dose, flavor and nicotine content of the product. Additionally, in an effort to determine 
the clinical relevance of these findings, I compare my results to those from an additional 
study examining gene expression differences in users of ECIG products.    
 
Aim 2: Determine whether different mutations in the airway epithelium alter the 
transcriptional response to cigarette smoke and cigarette smoke constituents. 
 Previous research into the impact of TCIG smoke exposure on airway epithelium 
has focused on histologically normal airway tissue 43,72,73,127. However, a number of step-
wise genetic mutations induced by TCIG smoke may alter normal airway tissue in a 
manner that is ‘pre-malignant’. In this chapter I begin to design a number of exposure 
experiments that will determine the transcriptomic impact of TCIG smoke and TCIG 
constituents on premalignant airway cells. These experiments will in the future inform 
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first, how cells harboring precancerous mutations respond to TCIG smoke and its 
constituents, second, how the biological response to individual TCIG constituents 
compares to that of whole TCIG smoke, and third, develop a novel methodology for in 
vitro high-throughput airway exposures.  
 
Aim 3: Generate a database of gene expression signatures from lung cell lines 
exposed to various small molecule compounds in order to identify novel lung 
therapeutics.    
 The Connectivity Map (CMap), built at the Broad Institute, uses gene expression 
profiling to find novel therapeutic uses for existing compounds. However, the gene 
expression profiles for this database are generated in cancer cell lines. With the 
hypothesis that cataloguing the response to treatment with therapeutic compounds in 
normal lung cells would identify more lung-relevant changes than the cancer cell lines, I 
seek to generate a Lung Connectivity Map or Lung CMap. Here, I aim to utilize gene 
expression profiling in a broader setting as a means to catalog airway response to diverse 
perturbations. In addition to building a high-throughput methodology for chemical 
exposures in primary cell lines, I design and perform a number of perturbations in which 
primary airway epithelial cells are exposed to drug and small molecule exposures 
previously profiled in CMap. Through these pilot studies, I determine lung-specific 
effects of exposure and evaluate the quality and utility of a Lung CMap.  
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CHAPTER TWO:  
Gene expression alterations in human bronchial epithelium following  
electronic cigarette exposure 
2.1 Background 
 The use of TCIGs remains the leading preventable cause of death in the United 
States, responsible for 6 million deaths per year, worldwide 20,21. Smoking is the primary 
cause of lung cancer, chronic obstructive pulmonary disease (COPD) and emphysema, 
and is also linked to heart disease and asthma 21.  
ECIGs are battery powered electronic nicotine delivery systems, which simulate 
tobacco smoking by delivering aerosolized nicotine. ECIG aerosols are generated by 
heating solutions of propylene glycol, vegetable glycerin, or similar mixtures together 
with nicotine and flavoring agents 87. ECIGs were first invented in 2003 and introduced 
to the U.S. in 2007, with sales surpassing 1.7 billion dollars in 2013 87. Since ECIG 
aerosols should not contain high levels of the many toxic tobacco combustion products 
present in tobacco smoke, ECIGs are thought by many to be a safer alternative to TCIG 
smoking 44,75. In 2015, 12.6 percent of all adults and 47.6 percent of current smokers had 
used ECIGs 102. In 2015, ECIGs were the most commonly used tobacco product among 
middle and high school students, with 16 percent of high school students identifying as 
active users of ECIGs (up from 1.5 percent in 2011) 107.  Increased advertising of these 
devices, the availability of attractive flavors, and the desire for nicotine alternatives in 
areas subject to indoor smoking bans have led to their popularity not only with current 
and former smokers but with non-smokers as well 33,102. 
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Despite the growing use of ECIGs in the U.S., few studies have evaluated the 
potential physiological impact of this exposure. These efforts have been complicated by 
variations in chemical composition between brands, individual cartridges, and differences 
in labeled values 24,41,124. Although there is some information on the physiological effects 
of ECIGs, the existing research has included indirect exposures 98, exposure of non-lung 
cell types 10 or only evaluated the e-liquid itself 54 rather than the aerosol produced from 
the complete ECIG product. Those studies that have investigated the effect of ECIG 
exposure on airway epithelium have focused specifically on aspects of toxicology, 
cytotoxicity and inflammation 5,66,82,101.  
Previously we have shown that airway epithelial gene expression is altered by 
TCIG smoking, and can be used as a biomarker for smoking-associated lung disease, 
including early detection of lung cancer 7,105,114 and molecular subclasses of COPD 
12,25,117. In this study, we aimed to determine the global gene expression effects of ECIG 
exposure in human bronchial epithelial cells grown at the Air Liquid Interface (ALI) 73,82 
and compare it with the effect of TCIGs. Of the approximately 450 brands of ECIGs on 
the market 101, we studied the effects of Blu ECIGs given that Blu is currently the largest 
producer of ECIG products in the world, and among the most popular brands in the 
United States, occupying 45 percent of the market share 101,122. Additionally, we 
compared our results to gene expression differences between bronchial epithelial samples 
collected from former TCIG smokers and former TCIG smokers who currently use 
ECIGs.  
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2.2 Materials and Methods 
In vitro HBEC culture. 
Primary human bronchial epithelial cells (HBECs) were isolated at MatTek Corp 
from the lungs of a 23-year-old Caucasian male nonsmoker donor with no history of 
respiratory disease obtained for research purposes with informed consent. The cells were 
grown using the EpiAirwayTM Air Liquid Interface (ALI) culture system as previously 
described 73. This 21-day culture method allowed for the differentiation of bronchial 
epithelium cell types similar to those seen in vivo including ciliated cells, goblet cells, 
club cells and basal cells. We performed standard EpiAirway quality control to ensure 
proper cell differentiation. 
In vitro exposure system 
Fully differentiated HBEC ALI cultures were exposed using a VitroCell Systems 
GmbH (Waldkirch, Germany) VC-1 smoking machine and 12/6 CF stainless-steel 
exposure module, as previously described 82. Smoke/aerosol puffed from the cigarettes by 
the smoking machine was diluted with clean air at a rate of 0.5 L/minute, before being 
drawn through the temperature controlled exposure chamber at a rate of 25 mL/min.  
Control cultures (sham treatment) were exposed to clean air only under the same 
conditions. Exposures were run in triplicate and included tobacco smoke generated from 
combustion of 3R4F reference cigarettes (University of Kentucky) that was drawn 
through the cigarette’s filter by the smoking machine similar to mainstream tobacco 
smoke. The ECIG exposures were generated from Blu-brand (Charlotte, North Carolina) 
disposables that were purchased from a retail source. These ECIGs were labeled as either 
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menthol or tobacco flavored, and without or with nicotine (24 mg per cartridge). A drill 
was used to widen the opening of the smoking machine’s cigarette holder as the ECIG 
was slightly wider than the TCIG.  Puff topographies were selected to mitigate toxicity 
and mimic physiologic exposure 11,34. TCIG exposures were performed using the ISO 
smoking regime (35 mL puffs with 1 min intervals) in accordance with ISO 3308:2012, 
using a 2 second puff draw, 8 second exhaust and a bell-shaped smoking curve. TCIGs 
were smoked to eight puffs/cig. ECIGs were puffed with an 80 mL puff drawn over 3 
seconds, 8 second exhaust, with 30 second intervals, and using a square-wave puffing 
profile, to actuate the electronic device 82. TCIG exposures were defined as 6 cigarettes 
(48 puffs), the maximum tolerable dose of TCIG exposure under the specific VC-1 
dilution and vacuum conditions utilized in the study, while ECIG exposures included 
450, 400, 200, 100 and 50 puff exposures with the same VC-1 dilution and vacuum 
settings. Sham exposures, with only clean air infused into the climatic chamber, were 
equal to the longest exposure time for TCIG (48 min) or EGIG (200 min) exposures. 
Exposed cells were also compared to ‘incubator controls’, HBEC cells grown under the 
same ALI conditions but not placed into the smoking machine. Following exposure, ALI 
cultures were fed with fresh maintenance medium (MatTek Corp) and incubated under 
standard conditions (37°C, 5% CO2) for 22-24 hours.  Cultures were then fixed in 
RNALater (Ambion) and stored frozen at -80ºC until processing for microarray and PCR 
gene expression assays.  
Study Designs 
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 Three sets of exposure experiments were performed. First, HBECs were exposed 
to 48 puffs TCIG smoke, or 450 puffs ECIG aerosol (Figure 2.1). ECIG exposures 
included tobacco flavor (with nicotine), tobacco flavor (without nicotine), menthol flavor 
(with nicotine) and menthol flavor (without nicotine). Cells were also exposed to 
corresponding air control. Second, HBECs were exposed to 48 puffs TCIG smoke, or 400 
puffs ECIG aerosol (Figure 2.2). ECIG exposures included tobacco flavor (with nicotine), 
tobacco flavor (without nicotine), menthol flavor (with nicotine) and menthol flavor 
(without nicotine). Cells were also exposed to corresponding air control. This experiment 
was then repeated, so that two batches of data were generated. Third, HBECs were 
exposed to 48 puffs TCIG smoke, or 400, 200, 100, 50 puffs ECIG (tobacco flavor with 
nicotine) aerosol (Figure 2.3). Cells were also exposed to corresponding air control. This 
experiment was then repeated twice, so that three batches of data were generated. 
 
Figure 2.1: First study design, exposure to 450 puffs ECIG aerosol. Design of study 1, including 48 puff TCIG, 450 
puff ECIG (flavor +/- nicotine) exposures and Air controls. Experiments peformed at MatTek Corp. 
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Figure 2.2: Second study design, exposure to 400 puffs ECIG aerosol. Design of study 2, including 48 puff TCIG, 
400 puff ECIG (flavor +/- nicotine) exposures and Air controls. Experiments performed at MatTek Corp. 
 
Figure 2.3: Third study design, exposure to different doses ECIG aerosol. Design of study 3, including 48 puff 
TCIG, 400, 200, 100, 50 puff ECIG aerosol exposures and Air controls. Experiments performed at MatTek Corp. 
RNA isolation and microarray gene expression profiling 
 Microarray gene expression profiling was performed on samples from the second 
study design. RNA was isolated using a standard Qiazol and Qiacube protocol from 
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Qiagen (Valencia, CA). RNA purity was assessed using a NanoDrop spectrophotometer 
and no samples were excluded from downstream analysis. 100 nanograms of high 
molecular weight RNA was processed and hybridized to Affymetrix Human Gene 1.0 ST 
Arrays (Affymetrix, Santa Clara, California). Probeset normalization and summarization 
were performed using Robust Multi-array Analysis (RMA) (CDF v17.0.0). These data 
have been uploaded to the Gene Expression Omnibus (GEO) under accession GSE82137.  
Microarray gene expression analysis 
 Data quality was assessed using relative log expression and normalized unscaled 
standard error metrics. Principal components analysis (PCA) was performed on the top 
2000 genes by median absolute deviation. A 1-way analysis of variance (ANOVA) 
(q<.05, fold change>1.5) was applied to detect major gene-expression differences across 
ECIG exposure and air control groups. Additionally, linear regression models were used 
to examine potential interaction effects between nicotine and flavoring additives in 
ECIGs. Differentially expressed genes were z-score normalized and hierarchically 
clustered using complete linkage clustering with a Euclidean distance metric. The gene 
dendrogram from the hierarchical clustering was cut using R’s cutree function to pro- 
duce clusters.  
Gene pathway analysis 
 Functional enrichment analysis was performed on gene expression data from the 
second study design. Cluster enrichment for biological pathways (p<0.01) from the Gene 
Ontology Biological Terms taxonomy was performed using the gene list enrichment 
analysis tool EnrichR 23. 
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PCR validation of select gene candidates 
Quantitative polymerase chain reaction (qPCR) was used to validate the 
differential expression of genes in all three study designs. Gene primers (GAPDH, 
CYP1A1, CYP1B1, CYP2A6, OPN, CEACAM6, MUC5AC, CC10, KRT5, FOXJ1, 
DNAH10, NQO1, PRDX1, IFT172) were obtained from SABiosciences (Valencia, CA). 
Total RNA (500ng) was reverse transcribed using SYBR Green reagents (Qiagen) and 
the resulting cDNA product was added to SYBR Green PCR Master Mix. All qPCR 
experiments were carried out in triplicate on each sample and the CT values were 
averaged. The average CT value was then normalized to the housekeeping gene GAPDH 
and fold change calculated relative to the average of the air controls. 
Reactive oxygen species measurement 
 The production of reactive oxygen species was determined by measuring levels of 
the ROS marker 8-isoprostane using an enzyme immunoassay from Cayman Chemical 
(Catalog #516351). This assay was performed using cell culture medium collected on the 
day following exposure. Media was frozen in 0.005% butylated hydroxytoluene at -80ºC 
and thawed immediately before use. The assay was then performed following the 
manufacturer’s protocol, in triplicate for each sample; sample replicates were averaged 
and then normalized to the average of the air control values. Concentrations of 8-
isoprostane in pg/ml are also included. 
Cell cycle analysis via flow cytometry 
 Quantification of DNA content corresponding to different phases of the cell cycle 
was performed using the propidium iodide flow cytometry kit for cell cycle analysis from 
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abcam (Catalog #ab139418). Cells from ALI cultures were washed with PBS and 
pelleted, and then fixed in 70% ethanol and stored at +4ºC. The assay was then 
performed following the manufacturer’s protocol and cells were washed twice with 
FACS buffer (PBS with 0.5% BSA and 2 mM EDTA) after staining and then analyzed on 
a FACSCalibur Flow Cytometer (BD Biosciences). FlowJo software (version 8.7; Tree 
Star) was used for final data analyses. Histograms were generated for each experimental 
replicate and representative histograms were selected. Cell counts were averaged for 
experimental replicates.  
Immunohistochemistry for AhR 
 Following exposure, cells were formalin-fixed and embedded in paraffin blocks. 
Sections (5 µm) were then cut from each block, deparaffinized and tissue rehydrated. 
Following a heat-induced antigen retrieval with citrate buffer, tissue was blocked using 
methanol and hydrogen peroxide, as well as 1% bovine serum albumin (BSA) in buffer, 
to decrease background staining. Tissues were then stained with primary antibodies to 
AhR or IgG1 control and followed with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody. Peroxidase activity was then revealed using DAB and slides 
were counterstained with hematoxylin and tissue dehydrated. Representative images at 
various antibody dilutions were then taken on a Nikon Eclipse Ti inverted microscope. 
Patient sample collection 
 Bronchial airway epithelial cells were obtained from brushings of the right 
mainstem bronchus taken during fiberoptic bronchoscopy with an endoscopic cytobrush 
(Cellebrity Endoscopic Cytology Brush, Boston Scientific, Boston). Samples were 
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collected from volunteer subjects at Boston University (BU) Medical Center and 
University of California Los Angeles (UCLA) Medical Center between March 2014 and 
May 2015. Institutional review board approval was obtained at both institutions and all 
subjects provided written informed consent. Volunteers were over the age of 21, not 
using marijuana, had no history of chronic lung disease and had no history of heart 
disease or other conditions that would increase the risk of undergoing bronchoscopy. 
Former smokers were required to have smoked at least 10 cigarettes a day for 2 years and 
to have abstained from TCIGs for at least 3 months prior to their visit. In addition, ECIG 
users were required to use an ECIG product at least six days a week, for at least one 
month. Smoking cessation compliance was monitored by measuring exhaled carbon 
monoxide.  
In vivo bronchial epithelial gene-expression microarray data generation 
 RNA was isolated from bronchial brushings using the miRNeasy mini kit and 
Qiacube from Qiagen. RNA integrity was assessed using an Agilent 2100 Bioanalyzer 
and RNA purity was assessed using a NanoDrop spectrophotometer. Samples from two 
volunteers were excluded due to a higher than expected exhaled carbon monoxide level at 
time of bronchoscopy. A total of 36 bronchial brushing samples passed quality control 
procedures and were used in downstream analysis. 100ng of high molecular weight RNA 
was processed and hybridized to Affymetrix Human Gene 1.0 ST Arrays. Samples were 
preprocessed using similar methods to in vitro arrays. A gene set representative of genes 
altered by ECIG exposure in vitro was derived and “up” and “down” regulated gene lists 
were created using a Student’s t-test between ECIG versus air exposed cells, and dividing 
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by the subsequent t statistic’s sign. To test whether these genes were concordantly 
changed among ECIG users, a LIMMA linear model 97,109 was run for each gene on the 
platform, with coefficients for smoking status (ECIG or former smoker), subject age and 
sample RIN. All genes were subsequently ranked by this model’s moderated t-statistic for 
the “ECIG vs. Former” coefficient, and thus by their association with ECIG exposure in 
vivo.  Gene set enrichment analysis (GSEA) was performed using this in vitro exposure 
gene set and in vivo derived ranked list using the JavaGSEA application 119,120. 
Statistical Analyses 
 Statistical significance of functional enrichment was determined by EnrichR 23. 
Statistical significance of differential gene expression, 8-isoprostane concentrations and 
cell numbers in the cell cycle analysis (with respect to air controls) was determined using 
the Mann-Whitney nonparametric t-test, and then post-hoc correction was performed 
using the Holm-Sidak method. Significant differences in age, race, sex, pack years, time 
since quit smoking or carbon monoxide between the Former smokers and ECIG users 
were accessed using a Fishers Exact test for categorical variables and a T-test for 
continuous variables.  
 
2.3 Results 
2.3.1 Preliminary Data 
 Previously, using the same smoking machine and ALI model, HBECs were 
exposed to varying doses of TCIG smoke, at different time points. Eddy Drizik, a 
research technician (Boston University) found that 48 puffs (6 cigarettes) TCIG smoke 
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altered gene expression in exposed cells, even after just 18 hours of resting time 
following exposure. These alterations in gene expression included the induction of AhR 
pathway, cytochrome P450 genes CYP1A1 and CYP1B1, which were both significantly 
induced with 48 puffs TCIG smoke exposure (Figures 2.4A and 2.4B). Longer exposures, 
of a higher dose, significantly altered the histology of the ALI cultures and induced 
significant cytotoxicity (data not shown). We therefore determined that this TCIG 
exposure would be appropriate for subsequent experiments.  
 
Figure 2.4: AhR Pathway genes are induced with TCIG exposure in vitro. Differential expression via qPCR of the 
genes (A) CYP1A1 and (B) CYP1B1 in HBECs exposed to 48 puffs (6 cigarettes) TCIG smoke. One experiment, n=3 
replicates. For all panels, levels are shown as fold change relative to the mean of the air controls, and error bars 
represent the standard error. Statistical significance of the change relative to air control was assessed by Mann-Whitney 
test and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. Performed by Eddy Drizik. 
2.3.2 Experimental design and lack of cytotoxicity following ECIG exposure 
With an adequate TCIG smoke exposure determined, cells were exposed to 450 
(full cartridge), 400, 200, 100, 50 puff flavored Blu brand ECIG exposures, per Figures 
2.1, 2.2 and 2.3. Our collaborators at MatTek Corp measured cytotoxicity via cell 
viability and transepithelial electrical resistance and found that exposure of HBECs to 
TCIG smoke resulted in a significant decrease in cell viability (Figure 2.5). But they 
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failed to detect significant decreases in cell viability when they exposed cells to 400 puffs 
of ECIG aerosol from a variety of Blu-brand ECIG products: tobacco-flavored without 
nicotine, tobacco-flavored with nicotine, menthol-flavored without nicotine, and 
menthol-flavored with nicotine (Figure 2.5C). While exposure to 400 puffs ECIG aerosol 
did cause a small loss in cell viability in Figure 2.5A, we saw a small increase in cell 
viability following the same exposure in Figure 2.5C. This inconsistency may be due to 
variations between products or between experiments.  
 
Figure 2.5: ECIG exposure does not induce cellular toxicity or changes in TEER. (A) Cell viability (expressed as a 
percentage of the air controls) measured via LDH levels in conditioned media. (B) Transepithelial electrical resistance 
(TEER) expressed as a percentage of the TEER measured pre-exposure. In panels A & B the exposures consisted of 6 
cigarettes (TCIG), 50 - 400 puffs of ECIG tobacco with nicotine, or air controls. Samples are pooled from two 
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experiments (n=12 samples). (C) Cell viability (expressed as a percentage of the air controls) measured via LDH levels 
in conditioned media for ECIG products that were either tobacco or menthol flavored ± nicotine (400 puffs), or 6 
TCIGs, or air controls. For all panels, error bars represent the standard error. Statistical significance of the change 
relative to air control was assessed by Mann-Whitney test with a post-hoc correction and is presented as * ≤ 0.05, ** ≤ 
0.01, *** ≤ 0.001, **** ≤ 0.0001. Performed by MatTek Corp. 
Next, given previous research indicating that TCIG smoke exposure alters cell 
cycle pathways, genes involved in cell cycle regulation, and induces apoptosis 74,88,130, we 
performed a cell cycle analysis to determine if TCIG smoke and/or ECIG aerosol would 
alter cell cycle transitions in human bronchial epithelial cells (Figure 2.6). We found that 
TCIG smoke-exposed cells had a distinctly different cell cycle profile from control air-
exposed cells, while the cell cycle profile of ECIG aerosol-exposed cells did not appear 
to be different from that of controls (Figure 2.6A). Specifically, TCIG-exposure 
significantly increased the number of subG1 (apoptotic) cells and significantly decreased 
the number of G0G1 cells and G2M cells (Figure 2.6B), indicating an increase in 
apoptosis and a decrease in cell growth and division following TCIG exposure. This 
phenotype was not seen in ECIG-exposed cells. We therefore determined that our ECIG 
doses were suitable for subsequent gene expression analysis.    
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Figure 2.6: TCIG exposure induces changes in the cell cycle that ECIG exposure does not. Cell cycle analysis was 
performed using propidium iodide staining and measured via flow cytometry. Exposures included 6 cigarettes (TCIG), 
400 puffs ECIG tobacco with nicotine flavored aerosol, and air (controls). Experiments were performed in triplicate. 
(A) Histograms of cells in subG1, G0G1, S, G2M stages of the cell cycle following ECIG exposure (left) and TCIG 
exposure (right), versus matched air controls. (B) Average cell counts in each stage of the cell cycle following each 
exposure condition. Error bars represent the standard error. Statistical significance of the change relative to 
corresponding air control was assessed by Mann-Whitney test with a post-hoc correction and is presented as * ≤ 0.05, 
** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
We next sought to confirm the validity of our air control exposures. We 
hypothesized that air controls (HBECs in ALI placed into the smoking machine with 
clean air puffed over the cells) would be a more suitable control than incubator controls 
(HBECs in ALI that never entered the smoking machine). We found that based on the 
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expression of CYP1A1, CYP1B1, FOXJ1 and DNAH10 genes, the production of reactive 
oxygen species, and cell viability, there was no difference between air and incubator 
controls (Figure 2.7A-C, E-F). These findings emphasize the importance of using air 
controls for isolating the specific effects of ECIG and TCIG exposure.  
 
Figure 2.7: Air control cells were not significantly different from incubator controls. Comparison of incubator and 
air controls via cell viability, gene expression and 8-isoprostane release. Exposures include incubator controls (HBECs 
which never entered the climatic chamber) and air controls (HBECs, “sham” exposures with only clean air infused into 
the climatic chamber). Statistical significance of the difference was assessed by Mann-Whitney test with a post-hoc 
correction and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. Error bars represent the standard error. 
(A) Cell viability (expressed as a percentage of the air controls) measured via LDH levels. For panels B-F, values are 
the fold change relative to the mean of the air controls. (B) qPCR of the dynein gene DNAH10. (C) qPCR of the 
ciliated cell marker FOXJ1. (D) qPCR of the cytochrome P450 gene CYP1A1. (E) qPCR of the cytochrome P450 gene 
CYP1B1. (F) 8-isoprostane levels. 
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2.3.3 Gene expression alterations following ECIG exposure 
We first examined global gene expression in TCIG- and ECIG- exposed cells 
using Affymetrix microarrays. To examine the overall effects of these exposures on gene 
expression, Dr. Teresa Wang (formerly of Boston University) performed a Principal 
Component Analysis (PCA) (Figure 2.8). Interestingly, the gene expression signatures of 
all four groups of cells exposed to ECIG aerosol clustered together, separately from 
TCIG-exposed samples along the first principal component, and separately from air 
controls along the second principal component, indicating both similarities and 
differences between the effect of ECIGs and TCIGs on HBEC gene expression. These 
results suggest that a major effect of TCIGs on airway gene expression is largely distinct 
from the effect of ECIGs. However, the second principal component identifies a 
variability in gene expression that distinguishes the TCIG- and ECIG-exposed HBEC’s 
from the Air-exposed HBECs, and reflects a response to TCIG-exposure that is shared 
with ECIGs. Importantly, the effects of flavoring and nicotine are not apparent in the first 
two principal components suggesting that they are less dramatic sources of gene 
expression heterogeneity. 
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Figure 2.8: Clustering analysis reveals that TCIG-exposed cells have distinct gene expression, but that some of 
these changes are shared with ECIG exposure. Principal component analysis of top 2,000 genes by median absolute 
deviation. HBECs exposed to TCIG smoke (red; n = 3), ECIG aerosol (purple/green; n =12) or Air (blue; n = 3). TCIG 
samples differ from Air controls and ECIG samples along the first principal component (accounting for 30% of the 
variability in gene expression), while both ECIG and TCIG samples differ from Air control along the second principal 
component (accounting for 23% of the gene expression variability). Performed by Teresa Wang. 
Next, Dr. Wang performed an ANOVA and identified 546 genes that were 
significantly differentially expressed (FDR q<0.05 and fold change>1.5) between ECIG-
exposed cells and air controls, and projected these genes into TCIG-exposed cells (Figure 
2.9). Dividing the gene expression into four clusters revealed that some gene expression 
changes following ECIG exposure were shared with TCIG exposure, while others were 
unique to ECIGs.  
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Figure 2.9: Shared/unique changes in gene expression with ECIG and TCIG exposure. Heatmap of the z-score 
normalized expression of genes that vary with exposure (546 genes, One-way ANOVA q<0.05 and fold change > 1.5 
for ECIG and Air-exposed groups, projected into TCIG-exposed cells). Genes were organized by hierarchical 
clustering and divided into 4 clusters. Performed by Teresa Wang. 
Dr. Wang next analyzed the gene expression response to flavoring and nicotine 
components of ECIG (Figure 2.10). She identified 493 genes as differentially expressed 
(p<0.005) between cells exposed to aerosol from ECIGs with menthol flavoring versus 
those exposed to aerosol from ECIGs with tobacco flavoring (Figure 2.10A). A similar 
analysis looking at differences associated with exposure to aerosol from nicotine 
containing ECIGs identified 162 genes with altered expression (p<0.005) (Figure 2.10B). 
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In both cases, the models indicated that gene expression altered by ECIG exposure was 
dependent on both flavor and nicotine content.  
 
Figure 2.10: Gene expression changes induced by ECIG exposure are dependent on flavor and nicotine. 
Differential effects of ECIG flavoring and nicotine on HBEC gene expression. (A) Heatmap of 493 genes (Student’s t-
test p<0.005) differentially expressed after exposure to aerosol from ECIG products containing menthol flavoring vs. 
tobacco flavoring. (B) Heatmap of 162 genes (p<0.005) differentially expressed after exposure to aerosol from ECIG 
products containing nicotine vs. those without nicotine (24mg nicotine per cartridge). Performed by Teresa Wang.  
Following the discovery of both shared and unique changes in gene expression 
following ECIG and TCIG exposure, we sought to understand these changes in further 
detail and determine their biological significance. We performed pathway enrichment 
analysis to identify whether genes with roles in specific biological processes or pathways 
are significantly altered by ECIG exposure. Based on hierarchical gene clustering, the 
546 genes significantly differentially expressed between the ECIG-exposed cells and air 
controls resolved into four main clusters in which gene expression was similarly or 
differently altered by ECIG and TCIG exposure (Figure 2.9). Cluster 1 contains genes 
that are similarly expressed at lower levels following ECIG or TCIG exposure, while 
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cluster 2 contains genes that are decreased in both exposure groups but more dramatically 
decreased following TCIG exposure than ECIG exposure. Cluster 4 consists of genes that 
are expressed at higher levels following either ECIG or TCIG exposure, whereas cluster 3 
contains a relatively small number of genes that were more highly expressed specifically 
following ECIG exposure. We found genes whose expression is down-regulated by 
exposure to ECIG and TCIG (clusters 1, 2) to be enriched for pathways related to cilium 
assembly and movement (Tables 2.1 and 2.2). Among the genes up-regulated by 
exposure to ECIG or TCIG (cluster 4), we found enrichment for pathways related to 
apoptosis, xenobiotic stress, oxidative stress and DNA damage (Table 2.4). Among the 
genes expressed more highly specifically in response to ECIG exposure (cluster 3), we 
found enrichment for pathways related to cell cycle regulation and cell division, 
including nuclear division and cytokinesis (Table 2.3).  
Enriched Pathway P-val 
microtubule-based process (GO:0007017) 9.11E-36 
cellular component assembly involved in morphogenesis (GO:0010927) 1.15E-32 
cell projection assembly (GO:0030031) 4.55E-32 
microtubule-based movement (GO:0007018) 2.62E-31 
cilium organization (GO:0044782) 1.20E-29 
cilium assembly (GO:0042384) 3.09E-26 
cilium movement (GO:0003341) 1.03E-23 
organelle assembly (GO:0070925) 1.38E-20 
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epithelial cilium movement (GO:0003351) 1.01E-14 
axonemal dynein complex assembly (GO:0070286) 1.03E-12 
intraciliary transport (GO:0042073) 1.51E-12 
axoneme assembly (GO:0035082) 3.83E-12 
microtubule bundle formation (GO:0001578) 1.03E-10 
spermatogenesis (GO:0007283) 4.91E-10 
male gamete generation (GO:0048232) 5.16E-10 
Table 2.1: Genes down-regulated with TCIG and ECIG exposure. Enriched biological pathways in genes down-
regulated with TCIG and ECIG exposure relative to air controls (Figure 2.9, Cluster 1). The top 15 enriched pathways 
are shown 
Enriched Pathway P-val 
cilium assembly (GO:0042384) 1.04E-08 
cilium organization (GO:0044782) 1.67E-08 
organelle assembly (GO:0070925) 1.39E-07 
cellular component assembly involved in morphogenesis 
(GO:0010927) 
4.22E-07 
cell projection assembly (GO:0030031) 1.25E-06 
antigen processing and presentation of exogenous peptide antigen via 
MHC class II (GO:0019886) 
8.55E-06 
antigen processing and presentation of peptide antigen via MHC class 
II (GO:0002495) 
9.06E-06 
intraciliary transport (GO:0042073) 9.77E-06 
antigen processing and presentation of peptide or polysaccharide 1.02E-05 
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antigen via MHC class II (GO:0002504) 
positive regulation of T cell activation (GO:0050870) 4.65E-05 
acute-phase response (GO:0006953) 5.57E-05 
antigen processing and presentation (GO:0019882) 0.00013 
positive regulation of lymphocyte activation (GO:0051251) 0.00021 
antigen processing and presentation of exogenous peptide antigen 
(GO:0002478) 
0.00022 
response to interferon-gamma (GO:0034341) 0.00022 
Table 2.2: Genes down-regulated with TCIG and ECIG exposure. Enriched biological pathways in genes down-
regulated with TCIG and ECIG exposure relative to air controls (Figure 2.9, Cluster 2). The top 15 enriched pathways 
are shown. 
Enriched Pathway P-val 
nuclear division (GO:0000280) 1.34E-07 
organelle fission (GO:0048285) 2.22E-07 
mitotic nuclear division (GO:0007067) 1.64E-06 
organ regeneration (GO:0031100) 0.0010 
cytokinesis (GO:0000910) 0.0024 
regeneration (GO:0031099) 0.0035 
regulation of mitotic cell cycle (GO:0007346) 0.0049 
doxorubicin metabolic process (GO:0044598) 0.0082 
daunorubicin metabolic process (GO:0044597) 0.0082 
cellular response to exogenous dsRNA (GO:0071360) 0.0082 
polyketide metabolic process (GO:0030638) 0.0082 
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regulation of mitotic spindle organization (GO:0060236) 0.0082 
regulation of cell cycle process (GO:0010564) 0.0086 
primary alcohol catabolic process (GO:0034310) 0.0091 
aminoglycoside antibiotic metabolic process (GO:0030647) 0.0091 
Table 2.3: Genes down-regulated with TCIG exposure and up-regulated with ECIG exposure. Enriched 
biological pathways in genes down-regulated with TCIG and up-regulated with ECIG exposure relative to air controls 
(Figure 2.9, Cluster 3). The top 15 enriched pathways are shown. 
Enriched Pathway P-val 
epidermis development (GO:0008544) 1.0017E-07 
response to nutrient levels (GO:0031667) 2.53E-06 
response to extracellular stimulus (GO:0009991) 4.98E-06 
cofactor metabolic process (GO:0051186) 5.48E-06 
epithelium development (GO:0060429) 5.67E-06 
keratinization (GO:0031424) 1.69E-05 
epithelial cell differentiation (GO:0030855) 2.33E-05 
keratinocyte differentiation (GO:0030216) 3.15E-05 
nitric oxide metabolic process (GO:0046209) 5.56E-05 
peptide cross-linking (GO:0018149) 6.24E-05 
response to starvation (GO:0042594) 6.78E-05 
response to oxidative stress (GO:0006979) 9.67E-05 
response to wounding (GO:0009611) 0.00010 
intrinsic apoptotic signaling pathway (GO:0097193) 0.00011 
negative regulation of protein serine/threonine kinase activity 0.00012 
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(GO:0071901) 
Table 2.4: Genes up-regulated with both TCIG and ECIG exposure. Enriched biological pathways in genes 
induced with TCIG and ECIG exposure relative to air controls (Figure 2.9, Cluster 4). The top 15 enriched pathways 
are shown. 
With regard to changes associated with flavor and nicotine, our pathway analysis 
of this expression profile revealed an enrichment for cell adhesion and protein 
polymerization related genes expressed at higher levels in the cells exposed to menthol 
flavored ECIG aerosol; and cell cycle and superoxide response related genes expressed at 
higher levels in the cells exposed to tobacco flavored aerosol (Tables 2.5 and 2.6). Genes 
up-regulated after exposure to nicotine-containing ECIG aerosol were enriched for genes 
involved in reactive oxygen species, epithelium differentiation and the cytochrome P450 
pathway, while down-regulated genes were enriched for genes involved in the response 
to inorganic substances (Tables 2.7 and 2.8).  
Enriched Pathway P-val 
response to amino acid (GO:0043200) 2.29E-05 
positive regulation of protein polymerization (GO:0032273) 6.36E-05 
positive regulation of cytoskeleton organization (GO:0051495) 7.14E-05 
regulation of cell projection assembly (GO:0060491) 0.00017 
regulation of protein polymerization (GO:0032271) 0.00023 
positive regulation of actin filament polymerization (GO:0030838) 0.00026 
regulation of actin filament polymerization (GO:0030833) 0.00052 
positive regulation of cellular component biogenesis (GO:0044089) 0.00062 
cellular response to lipopolysaccharide (GO:0071222) 0.00069 
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response to inorganic substance (GO:0010035) 0.00076 
cellular response to nitrogen compound (GO:1901699) 0.00088 
cellular response to molecule of bacterial origin (GO:0071219) 0.00090 
positive regulation of protein complex assembly (GO:0031334) 0.0012 
regulation of actin polymerization or depolymerization 
(GO:0008064) 
0.0012 
regulation of actin filament length (GO:0030832) 0.0012 
Table 2.5: Genes up-regulated with menthol flavored ECIGs. Enriched biological pathways in genes induced with 
menthol-flavored ECIG relative to tobacco-flavored ECIG (Figure 2.10A, Cluster 1). The top 15 enriched pathways are 
shown. 
Enriched Pathway P-val 
gene expression (GO:0010467) 2.97E-05 
regulation of RNA splicing (GO:0043484) 5.21E-05 
mRNA processing (GO:0006397) 5.49E-05 
RNA splicing (GO:0008380) 0.00010 
cell cycle checkpoint (GO:0000075) 0.00040 
mitotic cell cycle checkpoint (GO:0007093) 0.00047 
negative regulation of mitotic cell cycle phase transition 
(GO:1901991) 
0.00052 
negative regulation of cell cycle phase transition (GO:1901988) 0.00071 
negative regulation of mitotic cell cycle (GO:0045930) 0.0014 
negative regulation of cell cycle process (GO:0010948) 0.0015 
regulation of alternative mRNA splicing, via spliceosome 0.0017 
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(GO:0000381) 
negative regulation of cell cycle (GO:0045786) 0.0028 
chromosome organization (GO:0051276) 0.0028 
response to superoxide (GO:0000303) 0.0029 
anaphase-promoting complex-dependent proteasomal ubiquitin-
dependent protein catabolic process (GO:0031145) 
0.0032 
Table 2.6: Genes up-regulated with tobacco flavored ECIGs. Enriched biological pathways in genes induced with 
tobacco-flavored ECIG relative to menthol-flavored ECIG (Figure 2.10A, Cluster 2). The top 15 enriched pathways are 
shown. 
Enriched Pathway P-val 
peptide cross-linking (GO:0018149) 6.24E-05 
hydrogen peroxide metabolic process (GO:0042743) 7.80E-05 
epithelial cell differentiation (GO:0030855) 0.00013 
reactive oxygen species metabolic process (GO:0072593) 0.00023 
keratinocyte differentiation (GO:0030216) 0.00045 
response to wounding (GO:0009611) 0.00071 
epidermis development (GO:0008544) 0.0011 
epithelium development (GO:0060429) 0.0012 
epidermal cell differentiation (GO:0009913) 0.0015 
hydrogen peroxide biosynthetic process (GO:0050665) 0.0020 
omega-hydroxylase P450 pathway (GO:0097267) 0.0020 
reactive oxygen species biosynthetic process (GO:1903409) 0.0024 
cellular response to reactive oxygen species (GO:0034614) 0.0026 
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negative regulation of myotube differentiation (GO:0010832)  0.0028 
epoxygenase P450 pathway (GO:0019373) 0.0028 
Table 2.7: Genes upregulated with nicotine-containing ECIGs. Enriched biological pathways in genes induced with 
nicotine ECIG relative to non-nicotine ECIG (Figure 2.10B, Cluster 1). The top 15 enriched pathways are shown. 
Enriched Pathway P-val 
response to inorganic substance (GO:0010035) 0.0030 
cellular response to inorganic substance (GO:0071241) 0.0033 
rhythmic behavior (GO:0007622) 0.0037 
response to glucocorticoid (GO:0051384) 0.0052 
response to corticosteroid (GO:0031960) 0.0064 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.0069 
Table 2.8: Genes down-regulated with nicotine-containing ECIGs. Enriched biological pathways in genes down-
regulated with nicotine ECIG relative to non-nicotine ECIG (Figure 2.10B, Cluster 2). The 6 enriched pathways are 
shown. 
In all, functional enrichment revealed a number of pathways commonly altered by 
TCIG smoke and ECIG aerosol exposure in bronchial epithelial cells. It also identified 
pathways and functions altered only by ECIG exposure, and alterations specifically 
associated with different components of ECIGs. We first sought to further understand the 
gene expression changes shared with TCIG exposure.  
2.3.4 Shared differential gene expression with TCIG and ECIG exposure 
 Given the well-known effects of tobacco smoking, we first focused on gene 
expression alterations that may be shared between TCIG and ECIG exposure. We 
identified biological responses that have previously been established as being important 
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in the response to smoking 2,7,13,73,80,138 among the genes that are up-regulated in response 
to both ECIG and TCIG exposure. We found enrichment for genes related to the 
cytochrome P450 pathway, xenobiotic stress and oxidative stress response induced with 
TCIG and ECIG exposure (Figure 2.9, cluster 4; Table 2.4). Genes involved in these 
pathways were further induced by nicotine-containing ECIG aerosol (Figure 2.10B, 
cluster 1; Table 2.7). PCR validation of the aryl hydrocarbon receptor (AhR)-activated 
genes CYP1A1 and CYP1B1, as well as measurement of the production of reactive 
oxygen species, revealed a significant induction with TCIG exposure and all four ECIG 
exposures (Figures 2.11 and 2.12). This was true at ECIG exposures of 450 puffs (study 
design one, Figure 2.1)(Figure 2.11) and 400 puffs (study design two, Figure 2.2)(Figure 
2.12). Specifically, CYP1A1 was significantly up-regulated with exposure to TCIGs, 450 
puffs ECIG tobacco, tobacco with nicotine, and menthol with nicotine aerosol, and 400 
puffs ECIG tobacco with nicotine and menthol aerosol (Figures 2.11A and 2.12A). 
CYP1B1 was significantly induced with exposure to TCIGs, 450 puffs ECIG tobacco, 
tobacco with nicotine, and menthol with nicotine aerosol, and 400 puffs ECIG tobacco 
with nicotine, menthol, and menthol with nicotine aerosol (Figures 2.11B and 2.12B). 
Another cytochrome P450 gene, CYP2A6, previously shown to be down-regulated in 
bronchial epithelial cells of smokers 28, was down-regulated following exposure to TCIG 
smoke and 450 puffs ECIG tobacco with nicotine, menthol, and menthol with nicotine 
aerosol, in our study (Figure 2.11C). Finally, the production of reactive oxygen species 
(ROS), measured via the marker 8-isoprostane, significantly increased following 
exposure to TCIGs and 400 puffs ECIG tobacco and menthol with nicotine aerosol 
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(Figure 2.12C). Differences in the gene expression impacts of 450 and 400 puffs ECIG 
aerosol exposure again indicate heterogeneity between experiments.   
 
Figure 2.11: AhR Pathway/oxidative stress genes are altered with both TCIG and full cartridge ECIG exposure 
(450 puffs). Exposures include 6 cigarettes (TCIG), and 450 puffs ECIG menthol, ECIG menthol with nicotine, ECIG 
tobacco, ECIG tobacco with nicotine and control (air). n=3 samples which were run in triplicate. (A) qPCR of the 
cytochrome P450 gene CYP1A1. (B) qPCR of the cytochrome P450 gene CYP1B1. (C) qPCR of the cytochrome P450 
gene CYP2A6. For all panels, levels are shown as fold change relative to the mean of the air controls, and error bars 
represent the standard error. Statistical significance of the change relative to air control was assessed by Mann-Whitney 
test with post-hoc correction and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
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Figure 2.12: AhR pathway/oxidative stress genes and measures are similarly altered with TCIG and 400 puff 
ECIG exposure. Exposures include 6 cigarettes (TCIG), and 400 puffs ECIG menthol, ECIG menthol with nicotine, 
ECIG tobacco, ECIG tobacco with nicotine and control (air). Samples are pooled from two experiments (n=5 samples) 
and were run in triplicate. (A) qPCR of the cytochrome P450 gene CYP1A1. (B) qPCR of the cytochrome P450 gene 
CYP1B1. (C) Reactive oxygen species (ROS) production measured via 8-isoprostane enzyme immunoassay. For all 
panels, levels are shown as fold change relative to the mean of the air controls, and error bars represent the standard 
error. Average 8-isoprostane concentrations in pg/ml are shown for each exposure in the white boxes. Statistical 
significance of the change relative to air control was assessed by Mann-Whitney test with post-hoc correction and is 
presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
To determine whether the dose of ECIG (number of puffs of aerosol) influenced 
these gene expression changes, we exposed ALI cultures to 400, 200, 100 and 50 puffs of 
an ECIG with nicotine and tobacco flavoring (study design three, Figure 2.3), and 
measured CYP1A1 and CYP1B1 via PCR and oxidative stress via ROS production in the 
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cell culture media. While exposure to 400 puffs aerosol from an ECIG containing 
nicotine and tobacco flavoring highly induced both CYP1A1 and CYP1B1 relative to air 
controls, only CYP1A1 was significantly induced at lower doses (Figure 2.13A and 
2.13B). Interestingly, 8-isoprostane levels significantly increased with 400, 200 and 100 
puffs ECIG exposure as well as with TCIG exposure (Figure 2.13C). Therefore, ECIG 
and TCIG induction of xenobiotic and oxidative stress is dose-dependent and even small 
doses of ECIG aerosol can significantly induce these pathways of cellular stress.  
 
 Figure 2.13: Differential expression of AhR pathway/oxidative stress genes with ECIG exposure is dose-
dependent. Exposures include air control, 6 cigarettes (TCIG) and either 50, 100, 200 or 400 puffs from a tobacco-
flavored ECIG containing nicotine. Samples are pooled from three experiments (n=9 samples) and were run in 
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triplicate. (A) qPCR of the cytochrome P450 gene CYP1A1. (B) qPCR of the cytochrome P450 gene CYP1B1. (C) 
Reactive oxygen species (ROS) production measured via 8-isoprostane enzyme immunoassay. For all panels, levels are 
shown as fold change relative to the mean of the air controls, and error bars represent the standard error. Average 8-
isoprostane concentrations in pg/ml are shown for each exposure in the white boxes. Statistical significance of the 
change relative to air control was assessed by Mann-Whitney test with post-hoc correction and is presented as * ≤ 0.05, 
** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
 To further validate the activation of the AhR pathway with both TCIG and ECIG 
exposure in bronchial airway epithelium, we preliminarily stained for AhR using 
immunohistochemistry on ECIG- and TCIG- exposed bronchial tissue. Staining for AhR 
appeared to be increased in bronchial epithelium exposed to TCIG smoke and 400 and 
200 puffs ECIG aerosol (Figure 2.14). However, high background staining prevented us 
from being able to quantify this increase.  
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Figure 2.14: Activation of AhR with TCIG and ECIG exposure via immunohistochemistry. Immunohistochemical 
staining of bronchial epithelial cells in ALI exposed to TCIG smoke, 400, 200, 100, or 50 puffs ECIG aerosol, or 
control air. Cells were stained with an antibody for AhR, or for an IgG1 control, at a dilution of 1:15,000. All images 
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are taken at 40X magnification. Black arrows indicate positive staining. Experiments were performed in duplicate, 
representative images from each staining are shown. 
 Finally, while the previous gene expression changes were shared between 
multiple flavors of ECIG aerosol and TCIG smoke, certain changes are shared only 
between TCIG smoke and tobacco-flavored ECIGs. The AhR pathway gene OPN was 
significantly induced with exposure to TCIG smoke and 450 puffs ECIG tobacco and 
tobacco with nicotine flavored aerosol (Figure 2.15).  
 
Figure 2.15: AhR gene OPN is induced with TCIG, ECIG tobacco and ECIG tobacco with nicotine exposure. 
Exposures include 6 cigarettes (TCIG), and 450 puffs ECIG menthol, ECIG menthol with nicotine, ECIG tobacco, 
ECIG tobacco with nicotine and control (air). Samples are pooled from two experiments (n=5 samples) and were run in 
triplicate. qPCR of the gene OPN. Levels are shown as fold change relative to the mean of the air controls, and error 
bars represent the standard error. Statistical significance of the change relative to air control was assessed by Mann-
Whitney test with post-hoc correction and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
2.3.5 TCIG and ECIG exposure can remodel the airway epithelium 
 The proper differentiation of cells in the airway epithelium is crucial for 
maintaining its various functions. We next sought to determine what effect ECIG 
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exposure may have on the various cell types that make up the airway. We measured the 
expression of a number of cell marker genes including those for goblet cells (MUC5AC), 
club cells (CC10), ciliated cells (FOXJ1) and basal cells (KRT5) (Figure 2.16). We found 
that only TCIG exposure altered the expression of the goblet cell marker MUC5AC 
(Figure 2.15A). The Club cell marker CC10 was down-regulated after exposure to TCIG 
smoke, and 450 puffs ECIG tobacco, tobacco with nicotine, menthol, and menthol with 
nicotine aerosol (Figure 2.16B). Meanwhile the ciliated cell marker FOXJ1 was not 
significantly changed (Figure 2.16C). Finally, the basal cell marker KRT5 was down-
regulated following exposure to TCIG smoke, and 450 puffs ECIG tobacco and menthol 
with nicotine aerosol (Figure 2.16D).  
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Figure 2.16: TCIG and ECIG exposure alter the expression of airway epithelial cell markers. Exposures include 6 
cigarettes (TCIG), and 450 puffs ECIG menthol, ECIG menthol with nicotine, ECIG tobacco, ECIG tobacco with 
nicotine and control (air). We exposed n=3 samples which were run in triplicate. (A) qPCR of the goblet cell marker 
MUC5AC. (B) qPCR of the club cell marker CC10. (C) qPCR of the ciliated cell marker FOXJ1. (D) qPCR of the 
basal cell marker KRT5. For all panels, levels are shown as fold change relative to the mean of the air controls, and 
error bars represent the standard error. Statistical significance of the change relative to air control was assessed by 
Mann-Whitney test with post-hoc correction and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
Given the well established link between TCIG exposure and a reduction in 
ciliated cells in the airway epithelium, mucociliary clearance and a shortening of airway 
cilia 4,64,136, we sought to validate these findings suggesting that TCIGs and ECIGs both 
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cause a decrease in cilia-related gene expression (Tables 2.1 and 2.2). Using qRT-PCR, 
we validated the down-regulation of the structural cilia dynein gene DNAH10 and 
ciliated cell marker FOXJ1 with TCIG and 400 puffs ECIG exposure (Figure 2.17). We 
found that FOXJ1 was down-regulated by exposure to TCIG smoke, and 400 puffs ECIG 
tobacco and tobacco with nicotine aerosol (Figure 2.17A). Additionally, DNAH10 was 
down-regulated by exposure to TCIG smoke, and 400 puffs ECIG tobacco, tobacco with 
nicotine, menthol and menthol with nicotine aerosol (Figure 2.17B). In another instance 
of heterogeneity between experiments, while both TCIG and tobacco-flavored ECIG 
exposure altered FOXJ1 in these experiments, this gene was not altered in the previous 
experiments (Figure 2.16C). However, these data do suggest that ECIGs, similar to 
TCIGs, may interfere with ciliated cells in the airway epithelium. 
 
Figure 2.17: Cilia-related gene expression is down-regulated by TCIG and ECIG exposure. Exposures include 6 
cigarettes (TCIG), and 400 puffs ECIG menthol, ECIG menthol with nicotine, ECIG tobacco, ECIG tobacco with 
nicotine and control (air). Samples are pooled from two experiments (n=5 samples) and were run in triplicate. (A) 
qPCR of ciliated cell marker FOXJ1. (B) qPCR of structural cilia dynein gene DNAH10. For all panels, levels are 
shown as fold change relative to the mean of the air controls, and error bars represent the standard error. Statistical 
significance of the change relative to air control was assessed by Mann-Whitney test with post-hoc correction and is 
presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001.  
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Just as ECIGs induce some gene expression alterations that are specific to aerosol 
exposure, there are a number of changes that only exposure to TCIG smoke can induce in 
airway epithelium. Interestingly, the cilia assembly gene IFT172 was significantly down-
regulated with TCIG exposure, but not significantly different from air controls following 
exposure to 400 puffs ECIG aerosol (Figure 2.18).  
 
Figure 2.18: Cilia related gene expression is down-regulated by TCIG exposure. TCIG smoke exposure down-
regulates IFT172 while ECIG exposure does not. Exposures include 6 cigarettes (TCIG), and 400 puffs ECIG menthol, 
ECIG menthol with nicotine, ECIG tobacco, ECIG tobacco with nicotine and control (air). Samples are pooled from 
two experiments (n=5 samples) and were run in triplicate. qPCR of the cilia assembly gene IFT172. Levels are shown 
as fold change relative to the mean of the air controls, and error bars represent the standard error. Statistical 
significance of the change relative to air control was assessed by Mann-Whitney test with post-hoc correction and is 
presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
2.3.6 ECIG exposure can induce ECIG-specific gene expression changes 
 Given inherent differences in the makeup of ECIG aerosol and TCIG smoke, we 
next wanted to focus on gene expression changes specific to ECIG exposure. We found a 
number of genes whose expression was altered following ECIG aerosol exposure, but not 
following TCIG exposure. First, the AhR/oxidative stress gene NQO1 is up-regulated 
with 400 puffs ECIG tobacco with nicotine and menthol with nicotine aerosol exposure 
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(Figure 2.19A). Second, the oxidative stress gene PRDX1 is up-regulated with 400 puffs 
ECIG tobacco, tobacco with nicotine, and menthol with nicotine exposure (Figure 
2.19B). Together with previous data demonstrating a cluster of ECIG-specific gene 
expression (Figure 2.7, Table 2.3), these results indicate that ECIG exposure has a unique 
gene expression impact, distinct from other tobacco products. Further, these ECIG 
specific effects appear to be particularly evident in nicotine-containing products.  
 
Figure 2.19: Some changes in gene expression are ECIG-specific. The oxidative stress genes NQO1 and PRDX1 are 
significantly up-regulated with ECIG exposures but not TCIG exposure. Exposures include 6 cigarettes (TCIG), and 
400 puffs ECIG menthol, ECIG menthol with nicotine, ECIG tobacco, ECIG tobacco with nicotine and control (air). 
Samples are pooled from two experiments (n=5 samples) and were run in triplicate. (A) qPCR of the gene NQO1. (B) 
qPCR of the gene PRDX1. For all panels, levels are shown as fold change relative to the mean of the air controls, and 
error bars represent the standard error. Statistical significance of the change relative to air control was assessed by 
Mann-Whitney test with post-hoc correction and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001.  
2.3.7 Gene expression effects of ECIG exposure in vitro are similar to, but not identical, 
to in vivo ECIG use 
 In order to evaluate the physiological relevance of the findings from our in vitro 
exposure studies, we compared the effects we observed in vitro to gene expression 
profiles generated in bronchial epithelium samples from former cigarette smokers and 
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former smokers who use ECIGs (Table 2.9). By GSEA performed by Sean Corbett 
(Boston University), we found that the genes most up-regulated by ECIG exposure in 
vitro were significantly enriched (q<0.01) among the genes induced in ECIG users 
relative to former smokers while the genes most down-regulated by ECIG exposure in 
vitro were significantly enriched (q<0.01) among the repressed genes in ECIG users 
(Figure 2.20). These data suggest that the in vitro exposure system reflects the 
physiological effects of ECIGs experienced by ECIG users. 
 Former Smokers 
(n=21) 
Former Smokers,  
ECIG Users (n=15) 
P-val 
Age (years) 43 (10.7) 35.8 (10.4) 0.05 
Sex 11M / 10F 11M / 4F 0.30 
Race Multiple: 2 
AA: 5 
W: 14 
AI: 1 
AA: 3 
W: 11 
0.55 
Pack-Years 10.9 (10.5) 13.8 (11.3) 0.43 
Time since Quit 
(months) 
67 (117.5) 8.7 (4.4) 0.06 
Carbon 
Monoxide 
(ppm) 
2.3 (1.42) 1.857 (1.51)  
[1 N/A] 
0.35 
Table 2.9: Recruited former smokers and former smokers using ECIGs at BU and UCLA. Patient demographic 
information for bronchial brush samples collected from current smokers, former smokers and former smokers using 
ECIGs. Samples were collected at Boston University and University of California Los Angeles. Mean values are 
shown, with standard deviations in parentheses. P-values are shown for the difference between the three groups.  
P-values for gender and race were calculated by Fisher exact test. P-values for age, pack years were calculated by 
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Analysis of Variance. P-values for Time Since Quit and CO were calculated by a Student’s t-test. AA: Black/African 
American, W: White/Caucasian, AI: American Indian. 
 
 
Figure 2.20: Gene expression changes induced by ECIG exposure in vitro are enriched for changes in vivo. (Top) 
Enrichment plot showing the rank of genes with increased expression in vitro in the list of genes ranked from most 
increased to most decreased by ECIG use in vivo. Genes up-regulated with ECIG exposure in vitro are significantly 
enriched among the genes most induced in the airway of former smokers using ECIGs (n=15) (q<0.01). (Bottom) 
Enrichment plot showing the rank of genes with decreased expression in vitro in the list of genes ranked from most 
increased to most decreased by ECIG use in vivo. Genes down-regulated with ECIG exposure in vitro are significantly 
enriched among the genes most down-regulated in the airway of former smokers using ECIGs (n=15) (q<0.01). 
Performed by Sean Corbett.  
 
2.4 Discussion 
 We performed transcriptome profiling on differentiated bronchial epithelium 
exposed directly to ECIG aerosol in order to identify genes whose expression is altered 
by ECIG exposure. These findings provide novel insights into how ECIGs might 
potentially alter airway biology. By including TCIG exposure as a comparator, we were 
able to determine which gene expression changes induced by ECIG exposure are similar 
to the effects of TCIGs and which are unique. We focused our studies on four ECIG 
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products from a single manufacturer differing in flavoring and nicotine, allowing us to 
explore the effect of these ingredients. In addition, we characterized a full cartridge of 
ECIG aerosol (450 puffs), as well as lower doses of 400, 200, 100 and 50 puffs. It 
remains to be determined if other ECIG products produce similar effects. Our finding of 
concordant gene expression alterations in airway epithelial cells from individuals with 
real-world exposure to a variety of ECIG products mitigates this concern and more 
importantly, supports the physiological relevance of studying responses to ECIG 
exposures in vitro.  
We found that exposure to TCIG smoke or ECIG aerosol each induced gene 
expression changes in HBECs specifically related to xenobiotic metabolism, oxidative 
stress, DNA damage, apoptosis and cilia cell gene expression. Relative to air controls, the 
magnitude of shared gene expression changes was higher with TCIG exposures compared 
to ECIG exposures. In addition, our results indicate that these changes are more greatly 
induced by nicotine-containing ECIG aerosol than that of non-nicotine products and that 
the induction of AhR, CYP1A1, CYP1B1 and ROS production by ECIGs appears to be 
dose-dependent. Importantly, even in response to high dose ECIG exposure (450, 400 
puffs) the activation of xenobiotic and oxidative stress pathways is substantially lower 
than that seen with lower-dose TCIG exposure (6 cigarettes). Interestingly, additional 
genes in this pathway were altered in a different manner. OPN was specifically activated 
by tobacco exposures (TCIG and ECIG), While NQO1 was specifically activated by 
ECIG exposures containing nicotine. Activation of AhR and induction of the drug-
metabolizing cytochrome P450 genes is associated with tobacco smoke-induced disease, 
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including lung cancer 67,125. Our discovery of both shared and unique gene expression 
changes related to xenobiotic (and oxidative) stress in ECIG exposure emphasizes the 
unique profile that these novel products can induce, particularly with regard to cellular 
stress and its potential health effects. This prompts further examination into the 
relationship between ECIG use and lung disease. 
Oxidative stress and the increase in antioxidant genes in response to reactive 
oxygen species and oxidative damage has also been well established in smoking 
17,27,59,77,128 and recent publications have demonstrated the induction of oxidative stress by 
ECIG products in both cell culture and mouse models 65,66,101,121. Consistent with these 
prior publications, we found that the production of 8-isoprostane increases in HBECs 
after exposure to TCIG smoke or ECIG aerosol, suggesting a corresponding increase in 
reactive oxygen species. Interestingly, the production of 8-isoprostane appears at lower 
doses of ECIG aerosol than those required to induce gene expression differences. Since 
ROS are important mediators of inflammation and have been implicated in the 
pathogenesis of diseases such as COPD and lung cancer, the production of ROS in 
response to ECIG aerosol exposure would suggest the potential for downstream adverse 
health effects of ECIGs 66. It should be emphasized that as 8-isoprostane is a biomarker 
of ROS production, it will be valuable in the future to confirm the increased production 
of ROS by directly assaying these species using mass spectrometry. In addition, the 
oxidative stress genes NQO1 and PRDX1 were both increased specifically with ECIG 
exposure, indicating that exposure to ECIG aerosol may induce cellular stress that TCIGs 
do not.  
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We identified an additional group of genes whose expression is specifically 
induced in response to ECIG exposure that includes genes involved in cell cycle and cell 
division pathways. The 16 genes up-regulated only in ECIGs are the first identified to be 
expressed specifically in ECIGs, and further analysis of gene expression effects unique to 
ECIGs is warranted. In particular, it will be important to determine which product 
component or components are responsible for inducing these responses. 
It has been shown that TCIG smoke exposure can alter airway epithelial cell types 
84,94,136. To this end, we measured a number of epithelial cell markers following ECIG 
and TCIG exposure and found that indeed, both smoke and aerosol exposure altered the 
expression of goblet, club, cilia and basal cells. Additional genes with functions in cilium 
assembly and cilia movement pathways were also down-regulated after both TCIG and 
ECIG exposure. This decrease in cilia gene expression may reflect impairment of cilia or 
a decrease in the number of ciliated cells and suggests a potential defect in airway 
clearance, and an increased susceptibility to respiratory infection 64.  
Additional cilia-related changes were altered by TCIG smoke alone. Furthermore, 
TCIG smoke exposure induced cell apoptosis and decreased cell growth and division. 
Given the many carcinogens and genotoxic chemicals present in TCIG smoke that are not 
present in ECIG aerosol 49, we were not surprised to find a number of TCIG-specific 
transcriptomic effects. 
 Importantly, our analysis of in vivo bronchial epithelium samples from ECIG 
users indicated statistically significant similarities between the effects of ECIG exposure 
on gene expression in vitro and in vivo, suggesting that our in vitro findings are relevant 
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to the in vivo effects of ECIG exposure. This connection, which was recovered despite 
the heterogeneity of products and users profiled in our in vivo dataset suggests that 
detrimental effects of ECIG use identified in vitro may be present in vivo.  
There are a number of limitations to this study. Human bronchial epithelial cells 
were differentiated in an ALI system in order provide a more physiological system to 
measure the impact of ECIG aerosol. However, it is difficult to model the impact of 
chronic exposure that occurs in ECIG users using this relatively acute exposure system (< 
24 hours). Further, we profiled a relatively high dose of ECIG (450, 400 puffs) in vitro 
over a relatively short period of time based on the amount of aerosol that could be 
extracted from a single ECIG cartridge. However, recent studies 39 have indicated that 
based on nicotine content, 13 puffs e-liquid containing 18 mg/ml nicotine is equivalent to 
the smoke of one typical tobacco cigarette containing 0.5 mg nicotine. By these 
estimates, our 6 cigarette (48 puff) TCIG smoke exposure would be roughly equivalent to 
6 x 13 = 78 puffs of ECIG aerosol. 78 puffs per 48 minutes is a rate of exposure roughly 
similar to our experimental ECIG dose of 100 puffs per 50 minutes, at which we were 
still able to detect induction of both CYP1A1 and the ROS marker 8-isoprostane. The 
data from Geiss et al suggests that our 450 and 400 puff ECIG doses are substantially 
greater than the 48 puff TCIG dose with regard to delivered nicotine. The generally more 
dramatic effect of TCIG exposure on bronchial epithelial gene expression relative to the 
450/400 puff ECIG exposure therefore suggests that acute ECIG exposure is likely to 
have a less pronounced effect than acute TCIG exposure. However, larger sample sizes 
may increase our power to detect biologically relevant differences between TCIG and 
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ECIG exposure. For example, while we found no difference in air and incubator controls 
for a number of measures, these samples still had large standard errors for these assays. 
We therefore performed a power analysis and found that while our sample size of 5 
replicates per group for the cell viability assay yielded 45% power to detect changes at 
p<0.05, increasing the sample size to 10 replicates per group increased our power to 73%. 
In addition, comparisons for which the standard error was large, like the comparison 
between FOXJ1 expression in air and incubator controls, yielded just 8% power to detect 
changes at p<0.05 for our sample size of 5 replicates per group. Increasing this to 20 
replicates per group still only increased our power to 19%. Therefore, larger sample sizes 
are needed in order to increase our probability of detecting actual differences in our 
exposure conditions. Importantly, despite using only one brand of ECIGs and cells from a 
single donor for our in vitro exposures, our finding of similar gene expression changes in 
bronchial epithelial cells collected from users of diverse products supports both the 
physiological relevance of this system and the broad generalizability of the observed 
effects. These results have generated a number of specific biological hypotheses that can 
be tested in vitro and in vivo in future studies. 
Overall, this work represents one of the first characterizations of the effects of 
ECIG exposure on airway epithelium gene expression. In addition, validation of our in 
vitro findings in in vivo samples suggests that the exposure of differentiated airway 
epithelium to ECIG aerosol will be a useful approach to understand the cellular effects of 
ECIG aerosol.  Given the current lack of knowledge concerning the long-term health 
effects of ECIGs, we have focused our analysis on the aspects of the response to ECIG 
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aerosol that are similar to the response to TCIG smoke as TCIG smoke exposure is 
known to have deleterious health effects. Importantly, we found that similar to TCIG 
smoke, ECIG aerosol exposure induces xenobiotic, oxidative, and additional stress 
pathways, and potentially impairs ciliated epithelium. However, we found that these 
effects were generally more severe in response to TCIG smoke exposure, indicating that 
ECIG exposure may be less harmful. Still, given that these responses to TCIGs are 
thought to be related to their long-term health effects, these findings raise concerns 
regarding the safety of ECIGs use, despite their relative dissimilarity to TCIGs. Further 
investigations into the dissimilarity of ECIGs and TCIGs should be pursued, as these 
studies may uncover additional physiological facets of ECIG exposure that can manifest 
through long term ECIG use. 
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CHAPTER THREE: 
Cigarette smoke and its constituents may induce gene expression changes in 
premalignant lung cell lines 
3.1 Background 
 Despite progress in reducing the prevalence of TCIG smoking, it still remains one 
of the main preventable causes of death and disability, responsible for approximately 
431,000 deaths each year in the United States alone 110. Many of these smoking-related 
deaths can be attributed to incident lung cancer in current and former smokers, and lung 
cancer mortality rates are highly correlated with smoking prevalence 49. However, despite 
the well-established link between smoking and lung cancer, only 10 to 20 percent of 
smokers will go on to develop lung cancer 91,116. While some smokers may develop lung 
cancer at an early age, other heavy smokers may live well into their 90s with no evidence 
of cancer. Therefore it is important that we understand individual variations in biological 
response to TCIG smoke exposure.  
Cancer progression often results from the accumulation of permanent somatic 
mutations in critical genes, leading to clonal outgrowth and the development of a tumor 
22. Cigarette smoke exposure has been linked to a number of these somatic mutations and 
they can accumulate throughout the lifetime of an individual 1,22. It is therefore important 
that we understand the impact of continued TCIG exposure on airway tissue harboring 
mutations in cancer-related genes. Understanding this link between TCIG smoke 
exposure and genomic alterations can significantly inform our understanding of lung 
cancer progression. We hypothesize here that airway epithelial cells harboring mutations 
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in cancer-related genes may respond differently to TCIG exposure than wild-type cells. 
These cells harboring mutations in carcinogenesis-linked genes and pathways are often 
characterized by histologic changes that precede the development of invasive carcinoma, 
making them ‘precancerous’ 18,56. It is therefore important to understand the molecular 
alterations that connect TCIG exposure, the development of precancerous lung lesions, 
and lung cancer progression.  
 Furthermore, of the approximately 4,000 compounds found in TCIGs, 60 have 
been classified as known carcinogens, including polycyclic aromatic hydrocarbons 
(PAHs) like Benzo-A-Pyrene (BaP) and N-nitrosamines like NNK 42,47,48. Determining 
the exposure impacts of specific constituents of TCIG smoke will allow us to identify the 
phenotypic responses to particular carcinogens and potentially help improve the safety of 
these products by eliminating those chemicals that induce significant cellular stress. By 
utilizing airway cells harboring mutations commonly altered in lung cancer, we can 
determine the cellular response to TCIG smoke exposure in cells with precancerous 
mutations, and specifically identify the constituents of TCIG smoke that contribute to 
these responses.  
 Lastly, given the considerable number of chemical exposures our airway is 
subjected to throughout our lifetime, it has become imperative that we develop 
affordable, high-throughput methodologies to systematically characterize the 
transcriptomic impacts of these exposures. Current methodologies like microarrays and 
standard RNA-sequencing are time-consuming and expensive, and therefore not suitable 
for high-throughput exposures 104. In this study we profile microarrays as well as two 
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multiplexed RNA-seq protocols using 96-well plate exposures in order to design a new 
protocol for high-throughput exposure research that can be used not only to study the 
molecular impact of airway exposure but investigate exposures in other tissues as well.  
 
3.2 Materials and Methods 
Cell culture and exposure 
 Previously generated ‘premalignant’ cells (developed from SV40/hTERT 
immortalized tracheobronchial epithelial cells, AALEs and CRISPR/Cas9)(Table 3.1) 
were thawed from liquid nitrogen and grown up in SAGM small airway epithelial cell 
growth media (Lonza, Portsmouth NH). Cells were subcultured using Clonetics 
ReagentPack subculture reagents (Lonza, Portsmouth NH). In preparation for exposure, 
cells were plated into 24-well plates and allowed to reach confluency for 24 hours. Cell 
culture media was then replaced, and compounds added at a concentration of 24 µg/ml 
cigarette smoke condensate (CSC), 173µM BaP, 490µM NNK or DMSO, or left 
untreated). NNK and BaP compounds were obtained from Sigma-Aldrich (St. Louis MO) 
and CSC obtained from Murty Pharmaceuticals (Lexington, KY).   
Cell viability assay 
 Cell viability was measured using CellTiter-Glo Luminescent cell viability assay 
from Promega (Madison, WI). Following exposure performed in 96-well plates, cells 
rested for 24 hours in a temperature and oxygen-controlled incubator. Cells were then 
incubated at room temperature for 30min and the assay was performed following the 
manufacturer’s protocol, in triplicate for each sample. Luminescence values were 
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measured on a Promega GloMax Multi microplate reader. Sample replicates were 
averaged and luminescence measurements for media-alone was subtracted from 
experimental values. Cell viability was expressed in raw values and in percentage of 
DMSO-treated control wells. Inhibitory curves were built in Excel and corresponding 
IC10 values were calculated.  
RNA isolation and gene expression profiling 
 RNA was isolated using a standard Qiazol and Qiacube protocol from Qiagen 
(Valencia, CA). RNA purity was assessed using a NanoDrop spectrophotometer and no 
samples were excluded from downstream analysis. Quantitative polymerase chain 
reaction (qPCR) was used to validate the differential expression of genes. Gene primers 
(GAPDH, CYP1A1) were obtained from SABiosciences (Valencia, CA). Total RNA 
(500ng) was reverse transcribed using SYBR Green reagents (Qiagen) and the resulting 
cDNA product was added to SYBR Green PCR Master Mix. All qPCR experiments were 
carried out in triplicate on each sample and the CT values were averaged. The average 
CT value was then normalized to the housekeeping gene GAPDH and fold change 
calculated relative to the average of DMSO-treated controls. 
 
3.3 Results 
3.3.1 Preliminary Data 
 The cell lines utilized in this study were previously generated by Dr. Catalina 
Perdomo and Huiqing Si (Boston University). Using AALE tracheobronchial epithelial 
cells, Dr. Perdomo induced specific mutations using ORF or CRISPR/Cas9 technology 
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(Figure 3.1). Selected mutations (Table 3.1) are commonly found in lung cancer cells and 
were selected based on data from The Cancer Genome Atlas (TCGA) and the Pre-Cancer 
Genome Atlas (PCGA) 18, along with previous transcriptomic data.  
  
 
Figure 3.1: Generation of premalignant cell lines. Mutations were selected from TCGA and PCGA data, to identify 
commonly mutated pathways in cancer and lung cancer. AALE cells were then cultured and mutations induced using 
CRISPR and ORF technologies. 
Altered 
Gene 
TCGA Pathway PCGA Alteration Reagent 
FGFR1 Proliferation Up-regulated ORF/wt 
PI3KCA Proliferation Activation of AKT 
pathway 
ORF/mutant 
NFE2L2 Oxidative stress none ORF/mutant 
NRG1 YAP/TAZ Up-regulated ORF/wt 
FAT1 YAP/TAZ Mutated CRISPR 
CDKN2A Cell cycle Mutated CRISPR 
HCRED n/a n/a ORF 
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(control) 
GFP 
(control) 
n/a n/a CRISPR 
Table 3.1: Mutations in the eight ‘premalignant’ cell lines used in these experiments. All cell lines were generated 
from immortalized AALE cells. The six mutated genes are listed, along with two controls (one for each of the reagents 
used ORF and CRISPR). Mutations were selected from pathway alterations in TCGA and some were additionally 
altered in the PCGA. Pathways and alterations are listed. The reagent used to generate these mutations is also shown. 
wt = wild-type. ORF = open reading frame. 
3.3.2 Study Design 
 In this study, we sought to determine the gene expression effects of TCIG smoke 
and TCIG smoke constituents on premalignantly transformed airway cells. In our study 
design, we utilized the previously generated cell lines and several well-studied 
constituents of TCIG smoke. In addition, in order to fully understand the gene expression 
effects of these exposures, we plan to utilize multiple sequencing platforms. The full 
study design is shown in Figure 3.2.   
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Figure 3.2: Study design of TCIG constituent exposures in premalignant cells. Design of the planned study include 
eight ‘premalignant’ cell lines, four TCIG smoke exposures and three sequencing platforms. Mut = mutation. Ctrl = 
control. 
3.3.3 Determining time point and dose of exposure 
 Prior to designing the exposure experiments, we first sought to determine the 
ideal dose and time point for each of the selected compounds (cigarette smoke 
condensate (CSC) and TCIG constituents). In order to do this we exposed AALE cells to 
the three selected compounds and performed cell viability assays with the goal of 
identifying the 10% inhibitory concentration (IC10) dose for each exposure. We tested a 
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number of time points and doses (Table 3.2). Final cell viability assays from which we 
determined the IC10 of each compound are shown in Figure 3.3. Final IC10 doses for 
each exposure were calculated as 24 µg/mL CSC, 173 µM BaP and 490 µM NNK. 
Exposure Doses Time Points 
CSC 5, 10, 20, 30, 40, 60, 80, 100 µg/ml 24, 48, 72 hrs 
BaP 1, 2, 3, 4, 5, 8, 16, 32, 64, 128, 256 µM 24, 48, 72 hrs 
NNK 1, 2, 3, 4, 5, 10, 50, 100, 200, 500, 1000 µM 24, 48, 72 hrs 
Table 3.2: Tested doses and time points in the cell viability assays of CSC, BaP and NNK. For the three exposures 
(CSC and two TCIG constituents BaP and NNK), we tested a large range of doses and several time points for the 
exposure. Doses for CSC are in µg/ml and doses for BaP and NNK are in µM.  
 
Figure 3.3: Dose determination using cell viability assays of CSC, BaP and NNK. Cell viabilities presented as 
percentage of cell viability in DMSO controls. (A) Cell viability assay of AALE cells exposed to CSC. Doses 20-
100µg/ml. (B) Cell viability assay of AALE cells exposed to BaP. Doses 1-256µM. (C) Cell viability assay of AALE 
cells exposed to NNK. Doses 1-1000µM. All assays were performed after 24 hour exposure.  
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Lastly, in order to confirm that the identified IC10 dose of each exposure would induce 
changes in gene expression, we measured the expression of the cytochrome P450 gene 
CYP1A1, well-established to be activated by TCIG smoke (Figure 3.4). CYP1A1 was 
significantly up-regulated by all three TCIG compounds at the pre-determined dose.  
 
Figure 3.4: Validation of gene expression effects of selected doses, via PCR of CYP1A1. CYP1A1 expression 
measured via PCR of untreated, DMSO control, CSC, BaP and NNK exposed AALE cells. Levels are shown as fold 
change relative to the mean of DMSO controls, and error bars represent the standard error. Statistical significance of 
the change relative to DMSO controls was assessed by t-test and is presented as * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, **** 
≤ 0.0001. 
3.3.4 Final Exposure Experiments 
 Following the identification of dose and time point of exposure, we designed the 
final experiments. The eight premalignant cell lines would be exposed to CSC, BaP, 
NNK and DMSO (control) for 24 hours at the determined IC10 doses of 24µg/ml CSC, 
173µM BaP and 490µM NNK. Plate maps were designed as in Figure 3.5, with one plate 
per exposure. RNA was split between the three sequencing platforms so that all replicates 
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were profiled on all platforms. Exposure experiments have been performed and at the 
time of this writing sequencing on the three platforms has begun.  
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Figure 3.5: Plate layout for final CSC constituent exposure experiments (1 plate per exposure). Cell culture 24-
well plate layout for the 8 cell lines exposed to 3 TCIG exposures, CSC, BaP, NNK and DMSO controls, in triplicate.  
 
3.4 Discussion 
Given the substantial causal link between smoking and lung cancer, we seek to 
further explore the contribution of TCIG exposure and its constituents on the cellular 
alterations implicated in cancer progression. In this study, we exposed transformed 
airway epithelial cells to CSC and two TCIG constituents. These airway cells were 
transformed so as to include mutations commonly found in lung tumor cells or 
precancerous tissue. While the results of these exposures are forthcoming, a substantial 
amount of data has been produced in planning and generating these experiments.  
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 Transformed cell lines, mutated to induce a premalignant phenotype, were 
previously generated as part of the PCGA consortium. These cell lines provided a 
valuable resource to discern the intermediate events between normal airway epithelium 
and incident lung cancer. Selected mutations were involved in oxidative stress, 
proliferation and cell cycle pathways, frequently altered in tumor cells 46.  
Prior to performing our exposures, we sought to identify a dose of each compound 
that would (1) not induce significant cytotoxicity in AALE cells and (2) would induce 
changes in gene expression not below our level of detection. We first identified the IC10 
dose using a cell viability assay to ensure minimal cytotoxicity, and second, confirmed 
that this dose would induce measurable changes in gene expression by measuring the 
expression of a gene known to be activated by TCIG exposure, CYP1A1 67,79,125. 
 While we have previously researched the gene expression impact of TCIG smoke 
on normal airway epithelium 7,73,79 and the connection between smoker airway gene 
expression and lung cancer 8,112,114, the studies presented in this thesis provide an 
intermediary look at the step-wise progression of smoke exposure to lung cancer. In 
addition to examining the gene expression impact of CSC on transformed airway 
epithelium, we additionally included two influential and well-studied components of 
TCIGs, BaP and NNK. Previous research on the PAH BaP and tobacco-specific 
nitrosamine NNK has demonstrated BaP to be a potent carcinogen and mutagen which 
can increase the risk of human cancer 36,108,139 and that NNK has both mutagenic and 
carcinogenic effects, capable of inducing tumors in rodents 15,57. We therefore predict that 
while the gene expression impact of these TCIG constituents will be vast, their effects 
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will likely be additive when compared to the impact of CSC itself, which includes both 
BaP and NNK as well as a number of other carcinogens.  
 In addition, our use of three different sequencing methods will allow us to 
compare these platforms and their novel methodologies. First, Affymetrix microarrays 
will be used, the standard technology for large-scale studies of gene expression 140. 
Currently, microarrays remain the most popular approach for transcript profiling and can 
be readily afforded by many laboratories 140. But recent technology like RNA-
sequencing, the direct sequencing of transcripts by high-throughput sequencing 
technologies, has shown strong potential to replace microarrays as the go-to methodology 
for whole-genome transcriptome profiling 37,140. However, current methods of library 
preparation for RNA-seq are time-consuming and expensive to perform on many 
samples, since a single library is generated for a single sample 104. To reduce the cost and 
time of library generation, Shishkin et al have developed a protocol in which they attach a 
unique barcode to individual samples and pool these samples to generate a single RNA-
seq library 104. In addition, RNA sequencing technology has been expanded to profile 
single cells, as a promising tool for the characterization of heterogeneous populations. In 
order to profile large numbers of single cells at a reasonable cost, Soumillon et al have 
developed a 3’ digital gene expression (3’ DGE) RNA-Seq protocol 111. Profiling our 
exposures on these three sequencing platforms will allow us to fully evaluate changes in 
gene expression and the relationship between these alterations and the precancerous 
mutations induced in the exposed cell lines.  
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 At the time of this writing, the exposure experiments have been performed 
following the study design presented here. We believe that this data will substantially 
help us understand how TCIG exposure influences the step-wise progression of cancer 
and identify the significance of precancerous mutations in the cellular response to smoke 
exposure. Furthermore, the comparisons of the three sequencing platforms will allow us 
to identify an inexpensive, high-throughput mechanism to profile in vitro airway 
exposures.    
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CHAPTER FOUR: 
Distinguishing lung cell-type specific responses to therapeutic compounds 
4.1 Background 
 A large focus of clinical research is the identification of new treatments which 
enhance patient outcomes. Current identification of novel therapeutics often follows two 
pathways: novel drug discovery, and drug repurposing or repositioning 3. While novel 
drug discovery can take anywhere from 10 to 17 years, with less than 10% overall 
probability of success, and average cost of around 980 million dollars, drug repurposing 
has the potential to considerably reduce the time and money necessary to get the 
treatment onto the market given the ability to bypass many of the initial (and more costly) 
steps 3,78. 
The Library of Integrated Network-based Cellular Signatures (LINCS) 
Connectivity Map (CMap), developed by the Broad Institute of Massachusetts Institute of 
Technology and Harvard, is an exciting tool for drug repurposing that uses gene 
expression profiling to find novel therapeutic uses for existing compounds 62,95,113. 
Traditionally, gene expression profiling has been employed to predict cancer prognosis 
114, determine subtypes of disease 40, and identify mechanisms of a biological pathway 
62,63. The novelty of CMap arises from its ability to use gene expression to catalog 
biological response to diverse perturbations 62. Briefly, various cancer cell lines 
(including those of breast, lung, prostate, leukemia and melanoma) are treated with 
numerous compounds (perturbagens) representing a broad range of drug activities 62. 
Gene expression profiles are then generated for each perturbation (response of each cell 
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line to each compound) 62. Researchers then query the CMap database using their own 
gene expression signature of interest and compare it to the database profiles, allowing for 
the discovery of unexpected or previously undescribed connections 62. Gene expression 
profiles of interest may be signatures for exposure to carcinogen, premalignant tissue, or 
tumor tissue 62,113. When querying with a gene expression signature of disease, potential 
therapeutics can be identified as those that generate an anti-correlated pattern of gene 
expression 62,113. Previous success in drug repurposing via the CMap has successfully 
identified: three antipsychotics that also act to inhibit the proliferation of tamoxifen 
resistant breast cancer cells 51; the HSP90 inhibitor, Geldanamycin, as an inhibitor of lung 
adenocarcinoma cell growth 131; and ursolic acid (a natural component of apple skin) as a 
therapeutic for reducing muscle atrophy 60. 
More recent versions of the CMap involve gene expression profiling using the 
Luminex-1000 (L-1000) array 61 instead of microarrays. The L-1000 is a high-throughput 
gene expression signature analysis tool capable of measuring 1,000 landmark transcripts 
which each represent the behavior of a group of inferred genes 81,89. This technology 
utilizes two-laser flow cytometry and 500 different Luminex fluorescent colored beads to 
detect transcript identity and abundance 89. By measuring only 1,000 landmark genes, the 
L-1000 method is ideal for high-throughput screening given its significantly reduced cost 
compared to the standard microarray gene expression method 89.  
Previously our lab utilized the CMap to identify a small molecule tripeptide, 
glycine-histidine-lysine (GHK), which could reverse the gene expression profile of 
chronic obstructive pulmonary disease (COPD) 19. COPD (and emphysema) is 
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characterized by irreversible airflow limitation and is the fourth leading cause of death in 
the United States and the world 19,50. We queried the CMap with a 127-gene expression 
signature associated with regional emphysema severity 19. The compound GHK 
(previously implicated in wound healing and tissue remodeling 70,93,106) reversed the 
queried emphysema gene expression profile 19. GHK's ability to reverse the gene 
expression signature associated with emphysema severity was confirmed using GHK 
treated primary lung fibroblasts from COPD patients in comparison to healthy controls. 
Our desire to identify novel therapeutics for COPD is driven by the fact that there is 
currently no curative treatment. The results from this study indicated to us the potential 
benefit of a "lung-version" of the CMap, in which perturbations would be profiled on 
primary lung cell types in order to prioritize compounds for therapeutic discovery. These 
therapeutics could then help treat patients with incurable lung diseases like COPD. By 
generating an organ-based CMap, we can identify tissue-specific effects of drug 
perturbation and potentially extend this methodology to additional organ sites.  
 
4.2 Materials and Methods 
Cell Culture 
Cell lines included BEAS-2B bronchial epithelial cells (ATCC #CRL-9609), 
HBEC bronchial epithelial cells (Cell Applications #502-05a), A549 bronchoalveolar 
carcinoma cells (ATCC #CCL-185), HUVEC human umbilical vein endothelial cells 
(ATCC #CRL-1730), NL20 bronchial epithelial cells (ATCC #CRL-2503), 1HAE 
bronchial epithelial cells (gifted from Jim Hogg, UBC), IMR90 fetal lung fibroblasts 
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(ATCC #CCL-186), HFL1 fetal lung fibroblasts (gifted from Jim Hogg, UBC) and WI38 
fetal lung fibroblasts (ATCC #CCL-75). All cells were grown and maintained in Roswell 
Park Memorial Institute (RPMI) cell growth media supplemented with 10% fetal bovine 
serum (FBS) or ATCC recommended media, and subcultured with trypsin (0.25%)-
EDTA and phosphate-buffered saline (PBS). 
Cell Plating 
 Cells were plated into 384-well plates using an Apricot personal pipettor 
(Apricot) for the pilot experiments performed at BU or a Multidrop Combi (Thermo 
Fisher) at the Broad, at a density previously determined per cell line to ensure 100% 
confluency upon exposure (typically about 3500 cells per well). Total volume of cells 
was 45µL per well. Plates were incubated for 20 minutes at room temperature after 
plating to promote adherence before being moved to a 37ºC humidified atmosphere 
containing 5% CO2. After 24 hours, cell plates were removed from the incubator and 
prepared for treatment.   
Compound Exposure 
 - Pilot Study 
 For the pilot study, 19 compounds were selected based on interest of the 
investigators involved at BU (Table 4.1). Additionally, DMSO ‘vehicle’ controls were 
included as well as positive control compounds, selected due to consistent performance in 
the original CMap (LINCS). All compounds were obtained from Sigma-Aldrich with the 
exception of CSC (Murty Pharmaceuticals), CB0998 and CB3113 (Chembridge), TGFβ 
(PeproTech), KSFM media (Gibco), ECIG media (UCLA), and “TCIG combination”, 
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which was mixed in-house. Compound plating for the pilot study was performed at BU 
and compounds were diluted to 10mM and 20mM doses. Cell treatment was performed 
using the Apricot personal pipettor. In brief, a 384-well dilution plate was prepared 
containing 99µL RPMI media (10% FBS) per well. The Apricot machine transferred 1uL 
of compound from the compound plate to 99µL of RPMI on the dilution plate. The plate 
was then spun down for 1min at 1,000rpm. The Apricot then transferred 5uL from the 
dilution plate to 45µL of cells in the cell plates. Thus, the final concentration of 
compound exposure was 10µM and 20µM. Cell treatment was performed for 10 and 24 
hours.   
- Broad Experiments 
For the second study, 324 compounds from the drug management database at the 
Broad institute were selected for profiling (Table 4.4). Compounds were randomly 
selected from a list of 1,000 compounds previously profiled in the LINCS database and 
readily available for plating, including small molecules and drugs of various mechanisms. 
Additionally, DMSO ‘vehicle’ controls were included as well as positive control 
compounds, selected due to consistent performance in the original CMap (LINCS). 
Compound plating was performed at the Broad institute so that each well of a 384-well 
plate contained 10uL of compound at 10mM concentration. Cell treatment was performed 
using a 384-well CyBio liquid handling robot. In brief, a 384-well dilution plate was 
prepared containing 99µL RPMI media (10% FBS) per well. The CyBio transferred 1uL 
of compound from the compound plate to 99µL of RPMI on the dilution plate. The plate 
was then spun down for 1min at 1,000rpm. The CyBio then transferred 5uL from the 
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dilution plate to 45µL of cells in the cell plates. Thus, the final concentration of 
compound exposure was 10µM. Cell treatment was performed for 24 hours. 
Concentration and time point were selected to ensure comparability with the Connectivity 
Map, as the LINCS experiments used the same conditions. 
Cell Lysis 
 Following treatment, cells were lysed using the BioTek microplate washer 
(BioTek) for the pilot study, or CyBio at the Broad. First, the machine removed 35µL of 
media from each well of each cell plate. The machine then added 25µL TCL Buffer 
(Qiagen) to each well. Following cell lysis, plates were sealed with foil and incubated at 
room temperature for 30 minutes. Afterwards plates were frozen at -80ºC until ready for 
reverse transcription. For pilot experiments at BU, plates underwent an additional 
washing step prior to the addition of TCL buffer, to prevent transportation of potential 
carcinogenic compounds. For this step, the BioTek plate washer was used to wash the 
wells twice with 35µL PBS.  
Ligation Mediated Amplification and L1000 XMap Detection 
 Ligation mediated amplification and bead detection methods were followed as 
developed by the Broad, using the same protocols for both Lung CMap and LINCS 
CMap. 20µL cell lysate from the previous steps was transferred to Turbocapture plates 
for mRNA capture, lysate was removed by unsealing the plate and centrifuging face 
down on a super rag, and first strand cDNA was made using a 5µL per well master mix 
containing dNTPs and MMLV reverse transcriptase. Upstream and downstream probes 
for each gene were annealed to the first strand cDNA and each probe contained a barcode 
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for annealing to a Luminex bead in the detection process. cDNA was denatured at 95ºC 
for 2 minutes and ramped down from 70ºC to 40ºC over 6 hours. The probe pairs were 
ligated together forming a template for PCR. A 5µL master mix was prepared containing 
taq ligase in 1X ligase buffer, added to the plate and then incubated at 45ºC for 60 
minutes followed by a 65ºC hold for 10 minutes. The ligated probe template was PCR 
amplified using a set of universal primers. A 15µL master mix containing T3 and T7 
primers, dNTPs and hot start taq in a 1X reaction buffer was prepared and added to the 
plate and then loaded into a Thermo Electron MBS 384 Satellite Thermal Cycler for PCR 
amplification. After an initial denature step at 95ºC for 15 minutes, the plates cycled 29 
times at 60ºC. The primers annealed to the universal primer sites on the ligated probe 
pairs and the upstream primer contained biotin needed for staining. PCR amplicon was 
then hybridized to barcoded Luminex beads. The barcode incorporated in the amplicon 
was complementary to the barcode on each Luminex bead so that each gene annealed to a 
specific bead. A 5µL aliquot of PCR amplicon was transferred to a well containing 30µL 
bead mix (about 350 beads/gene/well) and the plate was sealed and incubated at 95ºC for 
2 minutes, and then at 45ºC for 18 hours. Following incubation, the plate was spun at 
3,000rpm for 1 minute to pellet the beads. The plate was then washed and stained for 
biotin.  
L1000 Data Processing 
 L1000 data processing was performed by the Broad Institute following their 
protocols, described in the manuscript Subramanian et al, “A Next Generation 
Connectivity Map:  L1000 platform and the first 1,000,000 profiles”, in preparation.  
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T-SNE plots 
 To capture a global perspective of the transcriptional profiles of perturbations in 
Lung CMap and the comparable subset of LINCS CMap, the t-SNE dimensionality 
reduction algorithm 69 was applied to the replicate collapsed, differential expression level 
data for both datasets. The algorithm’s default perplexity and learning rate parameters 
were utilized, and the data was collapsed into two dimensions. 
Compound Grouping 
 Initial compound groupings were identified using literature searches. Groups 
required at least 3 members, and compounds could be members of multiple, or no groups. 
A second round of compound grouping was performed by first identifying groups of 
compounds of distinct chemical structure that share the same mechanism of action. Those 
groups were then further refined by restricting membership to those compounds that 
individually recovered their expected relationships while also having similar gene 
expression signatures to at least 2 other class members resulting in Perturbagen Classes 
(PCLs).   
GEO Queries 
Gene expression datasets were selected from the Gene Expression Omnibus 32 due 
to their relevance to pulmonary disease pathogenesis. Each of these datasets was run 
through LINCS internal tooling, which automatically performs differential expression 
analysis between all treatment and control groups, yielding gene expression signatures 
(“gene sets”) of each exposure in each dataset. Each of these gene sets was queried via 
the sig_query LINCS tool, which generates a weighted connectivity score for each 
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perturbation. This score measures how enriched a given gene set is with that 
perturbation’s specific gene expression signature. Boxplots of weighted connectivity 
scores across all perturbations in each database were generated, and t-tests were 
performed between databases to identify scenarios in which query gene sets were 
significantly differentially connected between databases. 
 
4.3 Results 
4.3.1 Preliminary Data 
 Prior to performing our pilot exposures, we sought to prove that we could profile 
non-cancer, lung cell RNA on the L1000 array platform used by the Broad institute. To 
this end, we profiled previously isolated RNA from the GHK study in which we showed 
that the tripeptide compound GHK discovered with LINCS CMap could reverse a gene 
expression profile of emphysema and also restore a deficiency in collagen remodeling in 
COPD patient fibroblasts (indicative of a restoration of wound healing phenotypes) 19. 
The treatment scheme of the COPD patient-derived lung fibroblasts is outlined in Figure 
4.1, and fibroblasts were treated with GHK, TGFβ, and Angiotensin II. Additional 
treatments were selected based on GHK’s presumed mechanisms of action involving 
TGFβ. We found that GHK was able to reverse the gene expression changes associated 
with emphysema (Figure 4.2), similar to previous results using microarrays 19. We 
therefore validated that L1000 and microarray gene expression profiling yielded similar 
results.  
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Figure 4.1: Treatment scheme of fibroblasts treated with GHK. Primary lung fibroblasts were isolated from n=5 
healthy former smokers and n=10 former smokers with COPD. Fibroblasts were then either left untreated as controls, 
or treated with TGFβ, GHK or Angiotensin II.  
 
Figure 4.2: GHK was able to reverse a gene expression profile of emphysema (using L1000 technology). Similar 
to previous results using microarrays, L1000 gene expression profiling demonstrated a distinct emphysema gene 
expression profile (left), in comparison to healthy former smoker controls. In addition, GHK was able to reverse this 
gene expression profile of emphysema (right). N=115 genes, p<0.05. Samples are shown in columns, genes in rows. 
Genes in red are relatively up-regulated in that sample, gene in blue are relatively down-regulated. Performed by 
Teresa Wang. 
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4.3.2 Optimization and Design of the Exposure protocol 
 Following our validation that we could profile primary lung cell RNA on the 
L1000 gene expression platform, we performed a pilot study in order to optimize the 
exposure protocol for primary cell lines. Given that our preliminary data was generated 
from previously isolated RNA, we sought to ensure that using primary cell lines with the 
exposure protocol developed by the Broad (previously optimized for cancer cell lines) 
was feasible. The design of our pilot study is shown in Figure 4.3, and included five lung 
cell lines (four of which were primary, non-cancerous cell lines) (Table 4.1), and 19 
TCIG-related compounds, selected based on interest of the investigators involved (Table 
4.2). The 19 exposures included CSC and TCIG constituents, GHK and related 
compounds, AhR agonists/antagonists and ECIG treated media. Time points and doses 
were selected at the suggestion of the Broad institute, based on previous LINCS 
experiments.  
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Figure 4.3: BU Lung CMap pilot study design. We exposed five cell lines, HBECs and BEAS2B (bronchial 
epithelial cells), IMR90 (lung fibroblast), HUVEC (human umbilical vein endothelial cells) and A549 (bronchoalveolar 
carcinoma cells), to 19 TCIG-associated compounds. Exposures were performed at 10 and 20µM dose, for 10 and 24 
hour exposures. Experiments performed by Liz Moses. 
Cell Line Cell Type Source Donor(s) Notes 
HBEC Bronchial 
Epithelial 
Cell 
Applications 
Healthy 
individuals 
Primary 
BEAS2B Bronchial 
Epithelial 
ATCC Autopsy, 
noncancerous 
individuals 
Primary, 
SV40 
Immortalized 
IMR90 Fetal Lung 
Fibroblast 
ATCC 16 weeks 
gestation, 
Caucasian female 
Primary 
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HUVEC Umbilical Vein 
Endothelial 
ATCC Healthy 
individuals 
Primary 
A549 Bronchoalveolar 
Carcinoma 
ATCC 58-year old 
Caucasian male 
Cancer 
Table 4.1: Cell lines selected for pilot study. The five cell lines selected for exposures in the pilot study of Lung 
CMap. Table lists cell line name, cell type, source, donor(s) and any relevant notes, such as immortalization 
information. 
Compound Significance Notes 
Acetylaldehyde TCIG constituent  
Benzene TCIG constituent  
Isoprene TCIG constituent  
NNK TCIG constituent  
N-nitrosonornicotine TCIG constituent  
Propylene glycol TCIG constituent  
Nicotine TCIG constituent  
BaP TCIG constituent  
CSC TCIG exposure  
“TCIG Combination” TCIG exposure Combination of the five largest 
constituents of TCIG smoke 
ECIG Media TCIG-related  KSFM media exposed to ECIG 
aerosol 
KSFM Media TCIG-related  Media control for ECIG 
Indoxyl Sulfate AhR agonist  
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Benzo-E-Pyrene AhR agonist  
CB7903113 AhR antagonist Gifted from Dr. David Sherr 
CB7950998 AhR antagonist Gifted from Dr. David Sherr 
GHK GHK-related  
TGFβ GHK-related  
Pirfenidone GHK-related TGFβ inhibitor 
DMSO Control  
Wortmannin Positive Control  
Table 4.2: Compounds selected for pilot study. The 19 selected compounds included TCIG constituents, CSC, 
ECIG-exposed media, AhR agonists and antagonists, and GHK-related compounds. Plus two controls – DMSO and a 
positive control.   
Exposures were performed at BU, following the protocol developed by the Broad 
institute (Figure 4.4). Briefly, cells are plated into 384 well plates and then exposed to 
diluted compound following 24 hours of cell growth. After 10 or 24 hours of exposure, 
cells are lysed and frozen, and then subjected to L1000 gene expression profiling. 
Following L1000, data quality of the pilot study plates was found to be quite poor and 
only five of the 12 plates profiled passed quality control metrics. Poor data quality was 
likely due to the plate-washing step. Despite poor data quality, Dr. Wang analyzed the 
gene expression signatures of GHK and TGFβ, given their significance to our preliminary 
data. She found that GHK and TGFβ associated gene expression was concordant across 
the lung cell lines (Table 4.3).  
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Figure 4.4: Exposure protocol for CMap experiments. Overview of the exposure protocol. (1) Cells are plated into 
384 well plates. (2) Ahead of experiments, compound plate is generated by diluting compounds at necessary 
concentration to achieve desired dose upon additional dilution. (3) Dilution plate is filled with RPMI media. (4) After 
24 hours of growth, cells are exposed using a liquid handling robot. Robot will take 1µL compound from compound 
plate and add to 99µL media in dilution plate. Robot will then add 5µL diluted compound to media in cell plates. (5) 10 
or 24 hours after exposure, cells are washed in PBS and then frozen in TCL buffer for cell lysis. Cells can remain at  
-80C until ready for Luminex detection. (6) Plates are sent to the Broad and detected on Luminex XMap arrays. 
Experiments performed by Liz Moses. 
Cell Line Up-regulated with GHK and TGFβ Treatment 
Enrichment pval qval 
HUVEC 0.40 <0.001 <0.001 
A549 0.38 <0.001 <0.001 
IMR90 0.35 <0.001 <0.001 
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BEAS2B 0.23 0.15 0.14 
 Down-regulated with GHK and TGFβ Treatment 
Enrichment pval qval 
HUVEC -0.64 <0.001 <0.001 
IMR90 -0.61 <0.001 <0.001 
A549 -0.60 <0.001 <0.001 
BEAS2B -0.55 <0.001 <0.001 
Table 4.3: GHK and TGFβ-induced gene expression changes are concordant across lung cell lines. Enrichment of 
genes up- and down-regulated with GHK and TGFβ exposure in HUVEC, IMR90, A549 and BEAS2B cell lines. 
Genes up-regulated with GHK exposure were significantly enriched for genes up-regulated with TGFβ exposure in 
HUVEC, IMR90 and A549 cell lines, but not in BEAS2B. Genes down-regulated with GHK exposure were 
significantly enriched for genes down-regulated with TGFβ exposure in HUVEC, IMR90, A549 and BEAS2B cell 
lines. Statistical significance measured by fishers exact test and FDR. Analysis by Teresa Wang.  
Given difficulties in generating adequate L1000 data outside of the Broad 
institute, we decided to perform additional experiments at the Broad in order to follow 
their protocol as closely as possible. We followed the same protocol as in Figure 4.4, but 
experiments were all performed at the Broad, utilizing their instruments and equipment 
and eliminating the need for the plate-washing step (Figure 4.4, step 5). The study design 
was built based on previous LINCS experiments at the Broad, and our knowledge of lung 
cell lines (Figure 4.5).  
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Figure 4.5: Overall Lung CMap study design. We exposed 6 lung cell lines to approximately 325 randomly selected 
compounds from the CMap database, plus additional positive and negative controls. Compounds were exposed at a 
10µM dose for 24 hours. Selected cell lines included NL20 and 1HAE bronchial epithelial cells (red), WI38, IMR90 
and HFL1 fetal lung fibroblasts (green) and A549 bronchoalveolar carcinoma cells (blue). Experiments performed by 
Liz Moses. 
Per the Broad protocol, all cell lines are grown up in RPMI media supplemented 
with FBS prior to cell plating, however this method had been used only for cancer cell 
lines. We therefore wished to determine if growing primary lung lines in RPMI 
supplemented with FBS rather than the ATCC recommended media would affect their 
growth. This was particularly important given the large cell numbers that would be 
necessary for these experiments. We found that cell lines grown in RPMI grew at a 
similar, if not faster rate and appeared phenotypically similar, to those cells grown in 
ATCC recommended media after 24 hours growth in media (Figure 4.6). We therefore 
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followed the same method for our primary cells, and the Broad Lung CMap protocol is 
shown in Figure 4.7.  
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89 
Figure 4.6: Lung CMap cell lines grown in ATCC recommended media and RPMI supplemented with 10% FBS 
appeared similar in growth rate and visual phenotype. Six lung cell lines were thawed from cryovials stored in 
liquid nitrogen and plated in ATCC recommended media (left) or RPMI + 10% FBS (right). After 24 hours growth, 
cells were imaged. (A) 1HAE cells grown in recommended media or RPMI. (B) NL20 cells grown in recommended 
media or RPMI. (C) IMR90 cells grown in recommended media or RPMI. (D) WI38 cells grown in recommended 
media or RPMI. (E) HFL1 cells grown in recommended media or RPMI. (F) A549 cells grown in recommended media 
or RPMI. Cells in all panels appeared visually similar in size and shape, and cell numbers appeared to be similar, if not 
higher in RPMI-grown cells. Experiments performed by Liz Moses. 
 
Figure 4.7: Full Lung CMap protocol. Briefly, (1) Primary lung cell lines and one lung cancer cell line are grown in 
RPMI media supplemented with 10% FBS. (2) Cells are plated into 384-well plates, at previously determined 
concentration to achieve 100% confluency after 24 hours cell growth. (3) After 24 hours cell growth, compound 
exposures are added to the plates. CyBio liquid handling robot adds 1µL compound to dilution plate filled with 99µL 
RPMI media. Robot then adds 5µL diluted compound to cell plates. (4) After 24 hours exposure, cells are lysed and 
frozen in TCL buffer in preparation for reverse transcription. (5) Plates are stored at -80C until ready to use, then 
ligation mediated amplification is performed and transcripts detected on Luminex technology. (6) Data analysis, 
performed by Ted Natoli, Sean Corbett and Dr. Teresa Wang. Experiments performed by Liz Moses. 
 Since we followed the same protocols as the CMap team in generating our Lung 
CMap project, our datasets are quite similar. However, in comparison to the large LINCS 
CMap database, our Lung CMap project is a subset of that database (Figure 4.8). Both 
projects are profiled using L1000 technology, and include the A549 bronchoalveolar 
carcinoma cell line. In addition, the 325 compounds used in the Lung CMap exposures 
are also found in LINCS. Information about the cell lines used in our Lung CMap project, 
and the list of selected compounds are shown in Tables 4.4 and Appendix B, respectively.  
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Figure 4.8: Comparison of Lung CMap and LINCS CMap databases. Both databases are profiled using L1000 
technology, and share 325 compounds and the A549 cell line. Lung CMap profiles six lung cell lines, while LINCS 
profiles nine cell lines and an additional 1,675 compounds. Lung CMap therefore has approximately 2,100 signatures 
in comparison to the 50,000 signatures of LINCS CMap.  
Cell Line Cell Type Source Donor Notes 
1HAE/ 
16HBE 
Bronchial 
Epithelial 
Jim Hogg 
(UBC) 
1-year-old male Primary, SV40 
Immortalized 
NL20 Bronchial 
Epithelial 
ATCC 20-year-old 
caucasian female 
Primary, SV40 
Immortalized 
HFL1 Fetal Lung 
Fibroblast 
Jim Hogg 
(UBC) 
Unknown 
gestation 
caucasian 
Primary 
IMR90 Fetal Lung 
Fibroblast 
ATCC 16 weeks gestation 
caucasian female 
Primary 
WI38 Fetal Lung 
Fibroblast 
ATCC 3 month gestation 
caucasian female 
Primary 
A549 Bronchoalveolar 
Carcinoma 
The Broad 58-year-old 
caucasian male 
Cancer 
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Table 4.4: Cell line information for the six cell lines of Lung CMap. The six selected lung cell lines in Lung CMap, 
including cell type, source, donor and relevant information.  
4.3.3 Overall, data quality and compound performance are similar between Lung CMap 
and CMap 
 First, we wanted to validate the performance of the Lung CMap exposures in 
terms of data quality (in comparison to LINCS CMap) and overall gene expression 
response to exposures. To validate that the quality of data produced from the Lung CMap 
experiments was acceptable, Dr. Wang reviewed the overall gene expression and found 
that each lung cell line in Lung CMap exhibits a range of responses across the 325 unique 
perturbations. That is to say that the effects of each compound vary across different lung 
cell types. In addition, Dr. Wang found that compounds can elicit a range of responses 
across the six lung cell lines, with the overall gene expression impact of some compounds 
being highly concordant across the cell lines and others being highly discordant. Mr. 
Corbett also found that gene expression signatures in A549 cell lines, profiled in both 
Lung CMap and LINCS CMap, were significantly correlated. This indicates that gene 
expression profiling was overall similar between the two datasets. 
4.3.4 Compounds with a similar mechanism of action may induce similar changes in gene 
expression 
In order to identify commonalities in gene expression response following the 
Lung CMap compound exposures, we grouped the 325 compounds based on mechanism 
of action. We first grouped compounds based on established mechanism of action in the 
literature (Table 4.5), identifying 24 groups of 3-54 compounds. Compounds could be 
members of multiple groups. Second, Ted Natoli (Broad Institute), subsetted this list 
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based on previous performance in LINCS CMap perturbations (Figure 4.9). Specifically, 
compounds with a stated mechanism of action that induced a significantly different gene 
expression profile from 2 or more compounds with the same mechanism of action in 
LINCS were excluded from the grouping. This perturbagen class (PCL) analysis yielded 
19 groups of 3-16 compounds.  
Mechanism of Action Number of Compounds 
Antibiotic 12 
Antifungal 4 
Antiviral 8 
Insecticide 3 
Steroid 7 
PI3K Inhibitor 8 
BTK Inhibitor 3 
EGFR Inhibitor 19 
ERK/MEK/RAF Inhibitor 11 
NFkB Inhibitor 8 
HDAC Inhibitor 11 
HSP90 Inhibitor 5 
mTOR Inhibitor 7 
IKKB Inhibitor 4 
PKA Inhibitor 4 
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PKC Inhibitor 10 
Aurora Kinase Inhibitor 11 
CDK Inhibitor 10 
Bile Acid 6 
Anti-Inflammatory 23 
Cell Cycle Arrest 32 
Cell Death 54 
Anti-Angiogenic 19 
Oxidative Stress 8 
Table 4.5: Lung CMap compounds grouped by mechanism of action, method 1. Table of the 24 mechanism of 
action groups. Based on literature searches, mechanisms of action were compiled for all 325 Lung CMap compounds. 
Groups of compounds were created for mechanisms of action with at least three members. Compounds could be a 
member of multiple, or zero groups. Groupings performed by Liz Moses. 
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Figure 4.9: Lung CMap compounds grouped by mechanism of action, method 2 (PCL). Histogram of the 19 
mechanism of action groups or perturbagen classes (PCL). Based on both established mechanism of action via the 
literature, and previous performance in LINCS CMap perturbations, compounds were placed into groups. Compounds 
with a stated mechanism of action that induced a significantly different gene expression profile from the other 
compounds with the same mechanism of action in LINCS were excluded from the grouping. Analysis by Ted Natoli. 
Utilizing these compound groupings, we sought to identify gene expression signatures in 
Lung CMap of compounds with the same mechanism of action (Analysis by Sean 
Corbett, Figure 4.10). Ms. Moses found that these plots demonstrated that certain classes 
of compounds elicit a similar gene expression response (Figure 4.10A-C), while other 
compounds do not appear to induce a similar gene expression response based on 
mechanism of action (Figure 4.10D-F). Therefore, mechanism of action does influence 
gene expression response to perturbations.  
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Figure 4.10: Certain groups of compounds elicit a specific gene expression response, while other compounds do 
not induce similar gene expression changes based on mechanism of action. T-SNE clustering analysis of gene 
expression signatures in Lung CMap (compound exposure in a single cell line) colored (in blue) by compound class. 
Classes were identified by method 2 (PCL). (A) Gene expression signatures of lung cells treated with Topoisomerase 
inhibitors. (B) Gene expression signatures of lung cells treated with HDAC inhibitors. (C) Gene expression signatures 
of lung cells treated with HSP90 inhibitors. (D) Gene expression signatures of lung cells treated with FGFR inhibitors. 
(E) Gene expression signatures of lung cells treated with DNA Synthase inhibitors. (F) Gene expression signatures of 
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lung cells treated with Bile acids. X and Y axes represent the first and second T-SNE components. Analysis by Sean 
Corbett.  
4.3.5 Some compounds have a lung cell-type specific exposure response 
In addition to studying the overall gene expression impacts of compound 
exposure in Lung CMap, we also sought to determine if there were lung-specific effects 
of exposure to warrant additional studies and support the utility of organ-specific CMap 
profiling. Mr. Corbett performed a T-SNE clustering analysis which indicated that gene 
expression signatures clustered somewhat by cell line (Figure 4.11A). Further, Ms. 
Moses suggested that coloring the plots by cell-type may reveal additional biological 
significance. This revealed that these signatures further clustered by cell-type (Figure 
4.11B).  
 
Figure 4.11: Expression signatures cluster into cell type-specific responses. T-SNE clustering analysis of gene 
expression signatures in Lung CMap (compound exposure in a single cell line) appear to cluster by (A) cell line and (B) 
cell type. (A) T-SNE plot of Lung CMap gene expression signatures, colored by cell line (A549 (blue), 1HAE (red), 
NL20 (orange), HFL1 (green), IMR90 (purple), WI38 (yellow)). (B) T-SNE plot of Lung CMap gene expression 
signatures, colored by cell type (bronchial epithelial (red), lung fibroblast (green) and A549 cancer cells (blue)). 
Analysis by Sean Corbett.  
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4.3.6 Querying Lung CMap with gene signatures of lung disease indicates that Lung 
CMap may help prioritize compounds for drug repurposing 
The prime utility of LINCS CMap derives from querying, the ability to compare a 
gene expression signature of disease to the gene expression signatures of drug exposure 
in CMap. Given that the potential utility of Lung CMap would lie in querying with 
signatures of lung disease, we used Gene Expression Omnibus (GEO) 32 to build a list of 
lung-relevant gene expression signatures (Figure 4.12). The GEO datasets used to query 
Lung CMap and LINCS are presented in Table 4.6. 
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Figure 4.12: Overview of the GEO query list building protocol. GEO datasets for querying Lung CMap and LINCS 
CMap were built by searching GEO datasets with lung-relevant search terms. Gene expression signatures for querying 
were collected and then compared to the signatures in Lung CMap and LINCS. For example, genes up- and down-
regulated in the airway of patients with emphysema would be compared to both databases to identify compounds that 
could reverse this emphysema signature in cancer cell lines (LINCS) or lung cell lines (Lung CMap). GEO queries 
obtained by Liz Moses, queries performed by Sean Corbett.  
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GEO Number Title 
GSE43696 Severe asthma: bronchial epithelial cell 
GSE62769 Gene expression data of primary human bronchial epithelial 
cells exposed to crocidolite asbestos and cristobalite silica 
mineral dusts 
GSE49072 Alveolar Macrophage Gene Expression in Human Pulmonary 
Fibrosis 
GSE21369 Gene expression profiles of interstitial lung disease (ILD) 
patients 
GSE34607 Airborne particulate matter affects gene expression in BEAS-
2B bronchial epithelial cells 
GSE29133 Transcriptome in alveolar epithelial type II cells isolated from 
normal and COPD lungs of adult human 
GSE28835 Large airway epithelial cells from cigarette smokers with and 
without lung cancer undergoing flexible bronchoscopy in the 
operating room for resection of a suspicious lung nodule 
GSE4115 Airway Epithelial Gene Expression Diagnostic for the 
Evaluation of Smokers with Suspect Lung Cancer 
GSE58661 89 NSCLC patients with gene expression profiles and 
matching CT imaging data available at TCIA 
GSE51024 Gene Expression of Malignant Pleural Mesothelioma Tumor 
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and paired Normal Lung tissue 
GSE38958 Profiling of Gene Expression in Idiopathic Pulmonary 
Fibrosis 
GSE38003 Transcriptomic Analysis of Airway Smooth Muscle by Next-
Generation Sequencing (RNA-Seq): Asthma versus Healthy 
Controls 
GSE67472 Airway epithelial gene expression in asthma versus healthy 
controls 
GSE27011 Expression data from severe asthmatics, mild asthmatics and 
healthy controls 
GSE66499 Validation of an Airway Gene Expression Classifier for Lung 
Cancer in Patients Undergoing Diagnostic Bronchoscopy 
GSE19804 Genome-wide screening of transcriptional modulation in non-
smoking female lung cancer in Taiwan 
GSE43346 Gene repression with H3K27me3 modification in human 
small cell lung cancer 
GSE27597 A gene expression signature of emphysema-related lung 
destruction and its reversal by the tripeptide GHK 
GSE1650 COPD Study 
GSE37147 Bronchial airway gene expression reflects a COPD-associated 
field of injury that changes with disease severity and is 
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reversible with therapy 
GSE21411 Systems biology of interstitial lung diseases 
GSE38267 Gene expression profiling in blood of patients with chronic 
respiratory failure 
GSE2395 Human Cystic Fibrosis 
GSE18885 Expression data from human Wegener’s granulomatosis 
patients and normal controls in PBMCs and in PMNs 
GSE38934 Gene expression profiling of lung tissues from patients with 
combined pulmonary fibrosis and emphysema 
Table 4.6: List of lung-relevant GEO datasets used to query Lung CMap. GEO datasets were obtained using the 
protocol described in Figure 4.18, by searching the GEO database for lung and airway-relevant terms. Datasets were 
then used to query both Lung CMap and LINCS CMap to identify compounds capable of reversing these gene 
expression profiles. Datasets obtained by Liz Moses.  
Following, GEO dataset selection by Ms. Moses, Mr. Corbett next queried both Lung 
CMap and LINCS CMap using gene expression signatures of various lung disease and 
exposures (Table 4.6). It should be noted that the LINCS database used for queries was 
subsetted to the 325 compounds profiled in Lung CMap in order to ensure a direct 
comparison. After reviewing all query results, Ms. Moses selected queries with biological 
significance, which are shown in Figure 4.13. JAK inhibitors have been indicated as 
potential treatments for asthma 16,90. We found that when querying with a signature for 
asthma, JAK inhibitors were ranked more highly in Lung CMap than in LINCS CMap as 
being able to reverse this gene expression profile of asthma (Figure 4.13A). mTOR and 
PI3K signaling have both been implicated in the pathogenesis of idiopathic pulmonary 
fibrosis (IPF) and recently a combined mTOR/PI3K inhibitor has been used in clinical 
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trials to treat IPF 45,76. We found that mTOR and PI3Κ inhibitors were ranked more 
highly in Lung CMap for a query of IPF than in LINCS CMap (Figure 4.13B-C). In all, 
we ran 756 queries and found that in 712 cases there was no significant difference in the 
ability of a compound mechanism of action group to reverse the gene expression profile 
of the query (q>0.05). In 13 cases, a compound mechanism of action group ranked more 
highly in LINCS CMap than Lung CMap as being able to reverse the gene expression 
profile of interest (q<0.05), while a compound group ranked more highly in Lung CMap 
than LINCS CMap 31 times (q<0.05) (3 examples of which are shown in Figure 4.13). 
Overall, these results indicate that certain classes of compounds elicit lung-specific 
changes in gene expression, consistent with previous findings implicating these 
compounds and their mechanisms of action in the respective lung diseases presented 
here. Therefore Lung CMap may have utility in prioritizing compounds for drug 
repurposing.   
 
Figure 4.13: JAK inhibitors rank more highly in Lung CMap than LINCS CMap when querying with a 
signature for asthma, while mTOR and PI3K inhibitors rank more highly in Lung CMap than LINCS CMap 
when querying with a signature for IPF. Weighted connectivity scores of the most highly, negatively enriched 
compounds in LINCS CMap (left) and Lung CMap (right) when queried with a gene expression signature for asthma or 
IPF. Compounds with a high weighted connectivity score strongly reverse the queried gene expression signature. (A) 
Rank of the PCL JAK inhibitors in LINCS and Lung CMap for asthma query (GSE43696). JAK inhibitors ranked 
significantly higher in Lung CMap than LINCS CMap (q<0.05). (B) Rank of the PCL mTOR inhibitors in LINCS and 
Lung CMap for IPF query (GSE49072). mTOR inhibitors ranked significantly higher in Lung CMap than LINCS 
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CMap (q<0.05). (C) Rank of the PCL PI3K inhibitors in LINCS and Lung CMap for IPF query (GSE49072). PI3K 
inhibitors ranked significantly higher in Lung CMap than LINCS CMap (q<0.05). Analysis by Sean Corbett.  
 
4.4 Discussion 
 Given previous success of the LINCS Connectivity Map as a drug-repurposing 
tool, we endeavored to take an organ-specific approach and create a similar database 
specific to the lung and airway. To this end, we exposed primary lung cell lines to a 
subset of available drug compounds previously profiled in LINCS. By utilizing the same 
methodologies and drug exposures used in LINCS, we were able to draw comparisons 
between LINCS and Lung CMap and evaluate its potential utility. Through this series of 
pilot studies we were able to identify lung cell-type specific effects of exposure, 
suggesting that organ-specific exposure approaches may provide valuable insight into 
drug discovery for common diseases. These studies therefore validate the technology, 
methodology and utility of a Lung CMap.  
 We found that despite attempts to generate Lung CMap data in house, data quality 
was highest when we directly followed the protocols developed by the Broad. Indeed, 
many plates generated at BU failed quality control metrics, likely due to the washing step 
necessary for taking the plates off campus which seemed to remove large numbers of 
cells. For this reason, we generated subsequent plates at the Broad to avoid the plate-
washing step and ensure direct comparability between Lung CMap and LINCS by using 
the same equipment. We additionally limited our selection of exposure compounds to 
those profiled previously in LINCS. Finally, we confirmed that we could achieve 
adequate cell growth in our primary lung cell lines by growing all lines in RPMI media 
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(supplemented with FBS), as recommended by the Broad protocol. Following these 
adjustments, we found that data quality metrics from the Lung CMap experiments were 
highly similar to those of LINCS. However, despite poor data quality of our initial pilot 
plates, we were still able to observe enrichment of GHK and TGFβ gene expression in the 
lung cell lines initially profiled, consistent with preliminary data 19.  
 Prior to this work, we are unaware of any attempts to generate an organ-specific 
version of the LINCS Connectivity Map. We therefore first wanted to ensure that we 
could generate a similar gene expression database using the same methodologies. We 
included the A549 adenocarcinoma cell line in Lung CMap as it had been previously 
profiled in LINCS and would allow us to directly compare data between the two 
databases. We indeed found that exposure signatures in the A549 cell line were highly 
correlated between the two databases. While this was not surprising given our use of the 
same protocols, it was still an important validation. Furthermore, each cell line exhibited 
a range of responses to exposure, and therefore each unique perturbation generated a 
unique gene expression signature within each cell line. However, gene expression 
signatures appeared to be most consistent within a single cell type. In addition, most 
compounds elicited a range of discordant responses across all lung cell lines and 
therefore the response to exposure differed across cell lines. Only a quarter of the 325 
compounds profiled induced a concordant gene expression response in all six lung cell 
lines. Subsequent validations of mechanism of action and cell-type specific effects, as 
well as comparisons with signatures of lung disease distinguish these discordant 
responses from noise. Rather, these results indicate biologically interesting heterogeneity 
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in the response to compound exposure. Thus, we confirmed that we could observe 
exposure-specific changes in gene expression within and across lung cell lines. In 
addition, these results indicated that responses to exposure differed between distinct lung 
cell types. Hence we confirmed that gene expression responses to exposure were 
measurable in the Lung CMap, and data quality was consistent with that of LINCS.  
 It should be emphasized that the goal of this pilot study was to demonstrate lung-
specific effects of exposure, in order to warrant the creation of an expanded Lung CMap. 
The Lung CMap presented here is therefore a small subset of the vast LINCS consortium. 
While we profiled gene expression on the same Luminex platform, and included the 
A549 cell line, the 325 compounds exposed are only a subset of the 2,000 compounds in 
the published versions of LINCS and we profiled 6 lung cell lines in comparison to the 9 
GOLD standard cancer cell lines of LINCS. However, despite only profiling 2,100 
signatures (in comparison to LINCS’ 50,000) we still identified lung cell-type specific 
effects of exposure. Mainly, gene expression signatures in the lung cell lines of Lung 
CMap clustered distinctly by cell type. Therefore, cell type (bronchial epithelial, lung 
fibroblast and lung adenocarcinoma) strongly influenced the gene expression effects of 
compound exposure. In addition, certain classes of compounds induced similar changes 
in gene expression across all six lung cell lines, indicating that mechanism of action may 
play a role in compound exposure in the lung. Together, these data indicate that cell lines 
from lung resident cell types do indeed show specific responses to molecular 
perturbation.     
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 Finally, by querying both Lung CMap and LINCS CMap with signatures of lung 
disease, we sought to evaluate both the ultimate utility of a Lung CMap for drug 
repurposing, and also gain further insight into the biological relevance of our findings. 
We queried both databases with signatures for major lung diseases and airway exposure.  
When we compared the top negatively enriched compounds (therefore compounds most 
likely to reverse our gene expression profile of interest, and potentially treat the disease), 
we found that many compounds already in use to treat various lung diseases 
(mTOR/PI3K inhibitors in IPF, JAK inhibitors in asthma), were ranked more highly in 
Lung CMap than in LINCS CMap. In total, we found that more compound groups ranked 
more highly in Lung CMap than LINCS CMap (n=31/756) as being able to reverse 
signatures of lung disease, than those that ranked more highly in LINCS CMap 
(n=13/756). While these compound classes showed up in queries of both databases, the 
higher ranking of these compounds in Lung CMap suggests that Lung CMap may help 
prioritize compounds for drug repurposing. That is, by profiling normal airway gene 
expression, compounds with therapeutic potential have a more significant effect, and are 
more likely to be validated in vitro or in vivo. Lung CMap can therefore help prioritize 
compounds for validation and reduce the amount of time spent validating compounds that 
ultimately do not have therapeutic value in these diseases.  
 One caveat of these analyses is an inherent batch effect, since the LINCS CMap 
and Lung CMap exposures were run separately. Therefore it is difficult to determine 
whether differences in perturbation behavior between databases is due to biological 
effects (i.e. lung cell type specific responses), or simply due to batch effects. While we 
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are in the process of determining the best way to correct for this batch effect, this remains 
a limitation.  
In all, we were able to demonstrate lung cell-type specific responses to drug 
exposure. This pilot study therefore illustrates the potential utility of a larger Lung CMap 
database, and further argues for the creation of additional organ-based CMaps. 
Expansions of this study may include additional chemical perturbations, molecular 
perturbations, additional lung cell types and/or primary cells from patients with and 
without disease. Together, this data suggests that transcriptomic profiling of small 
molecule exposure has utility in the treatment of lung disease. 
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CHAPTER FIVE: 
General Conclusions and Future Directions 
5.1 Overall Discussion 
 Together, the chapters of this work seek to explore the molecular impact of 
chemical exposure on lung tissue. These works are further tied together through their use 
of gene expression profiling, high throughput in vitro models of exposure, and the use of 
airway epithelium as an indicator of the lung’s response to exposure. Further, segments 
of this work also seek to further understand the impacts of tobacco and tobacco-related 
exposures (chapters 2 and 3), components of cigarette exposure (chapters 2 and 3) and 
the connections between chemical exposure and the progression and treatment of lung 
disease (chapters 3 and 4).  
 Previous use of in vitro models of airway exposure have principally utilized 
simplistic, cell culture models, similar to our methods in chapter 3 29,31,35. Our use of first, 
the ALI and smoking machine exposures in chapter 2 enhances the physiological 
relevance of these findings by utilizing a model of the airway epithelium and exposure 
more akin to in vivo TCIG and ECIG use 73.  Further, our use of a 384-well culture 
system in chapter 4 demonstrates the utility of high-throughput exposure modeling, in 
order to substantially increase the number of exposures capable of being profiled in a 
single experiment. Together, these models demonstrate the feasibility of high-throughput 
in vitro modeling in exposure research, in comparison to labor-intensive mouse models 
and human sample collection. These models are particularly advantageous for gene-
expression outputs, in which downstream profiling is performed on a large scale. Smaller 
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scale modeling would therefore require multiple experimental repetitions in order to 
obtain the necessary quantity of input material for gene-expression profiling.  
 In addition, this body of work utilizes a number of different platforms to measure 
the molecular impacts of chemical exposure. In chapters 2 and 3, we utilize microarrays, 
often the standard of use for gene expression profiling 140. However, given inherent 
limitations of microarrays and the increasing use (and decreasing cost) of RNA-
sequencing, in chapter 3 we also profile two multiplexed RNA-seq platforms in order to 
evaluate the utility of these novel platforms in exposure research 104,111,140. These novel 
technologies may be better suited for high-throughput exposure profiling, given their 
ability to generate a single library for multiple samples 104,111. Drawing comparisons 
between the microarray and RNA-seq data will allow us to determine if further exposure 
experiments like those presented in this work may be better suited on a more multiplexed 
platform. One example of a high-throughput, reduced cost platform for gene expression 
profiling is the Luminex 1000 technology utilized in chapter 4. Given the scale of 
experiments necessary for the Connectivity Map exposures, the L1000 is the optimal 
platform for these exposures. Collectively, future comparisons of the four sequencing 
platforms utilized in this work may advocate for the optimal technology for high-
throughput in vitro exposures.   
 Additionally, these studies all utilize the airway epithelium as a model for 
chemical exposure in lung tissue. Chronic exposure may result in pathological 
remodeling of the airway epithelium, leading to changes in its barrier properties and 
interrupting mucociliary transport, all of which have the potential to compromise 
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pulmonary mechanics and the important functions of the epithelium 96. While chapter 2 
employs the normal human airway epithelium as a model for TCIG and ECIG exposure 
in the human lung, chapter 3 expands on this concept by further determining the impacts 
of TCIG and TCIG constituent exposure on transformed airway epithelium. These 
transformed airway cells, inclusive of six common genetic alterations in precancerous 
lung tissue, will allow us to understand the impact of TCIG exposure on the airway 
epithelium, and further draw comparisons between the response to exposure in normal 
airway, and airway cells harboring mutations commonly found in smokers. Lastly, while 
the Lung Connectivity Map experiments of chapter 4 also utilize the normal airway 
epithelium as a model for drug exposure, these experiments further characterize 
additional lung cell types, including fibroblast and bronchoalveolar cells. While the 
airway epithelium is an important model for exposure, our experiments in the Lung 
CMap have demonstrated strong cell-type specific differences in exposure between 
bronchial epithelial cells and other cells throughout the lung. Therefore, similar modeling 
of the molecular impact of TCIG and related exposures on additional lung tissue may be 
warranted. 
 Finally, the entirety of this body of work utilizes both experimental and 
computational analyses to identify alterations in gene expression and validate biologic 
responses to chemical exposure. The interplay of these methodologies demonstrates the 
utility of both metrics in understanding the impacts of airway exposure, particularly for 
high-throughput in vitro models, which can generate large amounts of rich gene 
expression data. Analysis of these complex datasets with standard experimental 
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techniques would be time-consuming and expensive. Bioinformatics allows us to sort 
through this breadth of data and identify pathway alterations for experimental validation 
that have biological and statistical significance. These experimental validations are 
particularly important for gene expression analyses, in which we often use functional 
enrichment analyses to identify biological pathways altered in our experimental 
condition. However, these functional enrichments present an inherent danger of making 
broad generalizations about biological significance. That is, they may identify an entire 
pathway as being altered by the condition based on demonstrated alterations in just a few 
genes. Therefore, combining these functional enrichment analyses with downstream 
experimental in vitro validations is essential for demonstrating the true biological impact 
of these genomic alterations. In the future, combining these experimental and 
computational methodologies can benefit exposure research and our understanding of the 
association between exposure and disease.    	
5.2 Overall Conclusions and Implications 
 The studies featured in this dissertation collectively seek to characterize the 
physiologic effects of chemical exposures on human airway epithelium, utilizing gene 
expression profiling and transcriptomic analyses. These exposures include cigarette 
smoke and its constituents, electronic cigarette aerosol, and a number of other established 
drugs and small molecules with known mechanisms of action and published therapeutic 
utility. Together, the results of these chapters assert that 1) exposure of airway epithelial 
cells to ECIG aerosol can induce gene expression changes similar to (but much lower in 
magnitude) TCIG smoke, 2) transformed airway epithelium may exhibit a differential 
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response to TCIG constituent exposure, and 3) exposure to small molecule therapeutics 
induce lung-specific and lung cell-type specific changes in gene expression.  
Gene expression alterations in human bronchial epithelium following 
electronic cigarette exposure 
 We found that exposure to ECIG aerosol induces significant changes in gene 
expression in the airway epithelium. Collectively, these changes are both similar to TCIG 
smoke exposure (including increases in xenobiotic and oxidative stress, and decreases in 
airway cilia genes), and unique to ECIG aerosol (including specific up-regulation of 
oxidative stress). Generally, the shared cellular stress alterations following both TCIG 
and ECIG exposure were much higher in magnitude following TCIG exposure. However, 
specific up-regulation of the oxidoreductases NQO1 and PRDX1 by ECIGs, and a higher 
increase in the production of reactive oxygen species following ECIG exposure indicate 
that increases in oxidative stress may be comparable between TCIGs and ECIGs. This 
finding is consistent with other published works, which found that ECIG products induce 
significant levels of oxidative stress in both in vitro cell culture models as well as mouse 
models 66,66,101,121. However, the implications of this increase in oxidative stress and 
xenobiotic stress remains to be seen. While increases in oxidative and xenobiotic stress 
pathways are common in response to toxicant and carcinogen exposure, this increase may 
serve as an attempt to detoxify these injurious agents and induce an antioxidant response 
following the induction of reactive oxygen species 30,103. Therefore increases in this 
oxidative and xenobiotic stress response may serve to actually ameliorate the injurious 
effects of ECIG aerosol exposure. However, our finding of significant increases in the 
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production of reactive oxygen species following ECIG exposure certainly raise concerns 
about their safety, and highlights the potential for protein oxidation, DNA damage and 
cell death following ECIG exposure 130. Currently, our efforts in continuing this ECIG 
research are focused on validating an increase in DNA damage following ECIG 
exposure. Further, we have yet to confirm that this xenobiotic stress increase is 
accompanied by AhR activation. We were unable to demonstrate AhR staining by 
immunohistochemistry, however, a better validation of this receptor’s activation would 
be a knockdown experiment in which we knockdown the expression of the AhR in our 
bronchial epithelial cells prior to ECIG exposure. Should we lose this CYP1A1 
expression and other indications of xenobiotic stress following AhR knockdown, then we 
can conclude that AhR is indeed activated in these cells following ECIG exposure. We 
may also perform a similar experiment with one of the AhR inhibitors used in our pilot 
study experiments in chapter 4. The decrease in cilia gene expression following ECIG 
and TCIG exposure also raise concerns about their safety. TCIGs have previously been 
shown to reduce numbers of ciliated cells in the airway epithelium, as well as shorten 
airway cilia and impair mucociliary clearance 4,64,136. The association of ECIG exposure 
with this response is highly concerning, suggesting that ECIG use may impair the 
mucociliary clearance function of the epithelium and promote susceptibility to respiratory 
infection, thereby disrupting the typically sterile environment in the lower respiratory 
tract 64,136. While these alterations are common to TCIG exposure as well, we did find a 
number of gene expression changes specific to ECIG exposure. These unique alterations 
were enriched for genes involved in cell cycle and nuclear division, however, we have yet 
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to determine the biological significance of this finding, having identified no significant 
differences in cell cycle activity between ECIG-exposed and control cells. Despite this, 
these genes are the first identified to be expressed specifically in ECIGs, and further 
analysis of gene expression effects unique to ECIGs is warranted. In particular, it will be 
important to determine which product component or components are responsible for 
inducing these responses. Profiling additional flavors, brands and devices of ECIGs will 
provide further insight into these ECIG-specific changes, as we only profiled one device, 
one brand and two flavors of ECIG products (with and without nicotine). However, with 
the increasing number of brands and flavors, and introduction of new generations of 
devices, it has become increasingly imperative to profile a larger sample of products to 
ensure that our data is relevant to current ECIG users 101. The high-throughput gene 
expression profiling systems employed in this chapter as well as chapter 3 will be vital to 
performing these large-scale exposures. Further, profiling additional products may allow 
us to determine the specific components of ECIGs that induce ROS and the specific 
pathway by which these ROS are induced 58. Identifying these components will allow us 
to improve the safety of future ECIG products by excluding those components that 
induce oxidative stress.  
 Cigarette smoke and its constituents may induce gene expression changes in 
premalignant lung cell lines 
 Determining the interaction between TCIG exposure and genetic mutations is 
crucial to understanding the pathogenesis of lung cancer, given that cancer progression 
often results from the accumulation of permanent somatic mutations in critical genes 22. 
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Further, TCIG exposure has been linked to a number of these somatic mutations and they 
can accumulate throughout the lifetime of an individual 1,22. Therefore, it is imperative 
that we understand the impact of continued TCIG exposure on airway tissue harboring 
mutations in cancer-related genes. For instance, CDKN2A, a gene lost in 72% of lung 
squamous carcinomas 86, is an important tumor suppressor that negatively regulates cell 
growth by arresting cells in the G1 phase and inducing apoptosis.  In normal cells 
exposed to TCIG, the CDKN2A check point pathway gets activated if sufficient DNA 
damage is sensed. However, in cells harboring loss of function CDKN2A alterations, this 
checkpoint is impaired and thus the cells continue to proliferate abnormally despite 
activation of the intranuclear mechanisms that signal apoptosis or cell cycle arrest. 
Understanding these links between TCIG exposure, mutation, and cancer progression 
may provide insight into the clonal evolution of lung cancer. Further, by evaluating the 
transcriptomic impact of TCIG constituents, we can identify the components of tobacco 
smoke that interact with the specific genetic mutations profiled in this study. We have 
initially profiled just two major TCIG constituents, BaP and NNK, however there remain 
over 40 known carcinogens and nearly 4,000 additional components of TCIGs 47. 
Profiling these compounds in the high-throughput in vitro system developed in this study 
may potentially help improve the safety of TCIGs by eliminating those chemicals that 
induce significant cellular stress. We have currently profiled six mutations relevant to 
TCIG smoke exposure and lung carcinogenesis, however given the sheer number of 
mutations that are statistically possible to contribute to lung cancer progression it will be 
important to profile additional mutations. While our initial selections of mutations were 
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based on the literature, TCGA and our initial PCGA dataset, further insights from the 
PCGA may help to inform the selection of additional mutations 18. Furthermore, this 
study has additional implications not only for the study of lung cancer but in identifying 
an optimal gene expression platform for high-throughput exposure profiling. An 
affordable, high-throughput system will be necessary if we are truly to profile the 
additional 4,000 constituents of TCIG smoke in the same manner.  
 Distinguishing lung cell-type specific responses to therapeutic compounds 
 With so many therapeutics on the market, with numerous indications, profiling 
drug compounds requires affordable, high-throughput systems in order to adequately 
study a meaningful number of drugs. To this end, we used high-throughput robotics and a 
384-well system to profile 325 small molecule therapeutics. While this system has been 
used previously in the LINCS CMap to profile thousands of drugs in various cancer cell 
lines, this is the first published instance of using non-cancerous cell lines on the same 
platform 62. Furthermore, this is the first successful use of this system to profile non-
immortalized cells. As non-immortalized cell lines have a limited lifespan in culture 
compared to immortalized cell lines 71, it was not previously thought that non-
immortalized cells would be feasible for use in such a high-throughput system. After 
optimizing the exposure protocol for use on immortalized and non-immortalized lung 
cells, we found that there were cell-type specific responses to drug exposure. 
Specifically, the response to perturbation in bronchial epithelial cells, differed from that 
of fetal lung fibroblasts, and both differed from A549 bronchoalveolar carcinoma cells. 
While these results were exciting and intriguing, fibroblasts and epithelial cells make up a 
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small percentage of the cells found in the normal human lung 26. Therefore, profiling of 
additional cell types, like smooth muscle cells, alveolar macrophages and endothelial 
cells would provide further support for these cell-type specific effects to exposure in the 
lung. Further, we found that certain classes of compounds induced a specific gene 
expression signature in the lung cells, indicating that mechanism of action may play a 
strong role in the gene expression response to exposure. However, a large number of 
compound groups did not display this same signature clustering, and it remains to be seen 
whether any conclusions can be made regarding the types of compounds that do and do 
not induce these common changes in transcriptomic response. Finally, querying of the 
Lung and LINCs CMaps revealed that certain compound classes, with previously 
published therapeutic utility in lung disease, more strongly reversed gene expression 
profiles of lung disease in Lung CMap than they did in LINCS. This may indicate that 
Lung CMap could help prioritize compounds for drug repurposing, however it does not 
suggest that querying Lung CMap would identify potential therapeutics that LINCS 
CMap cannot. However, expansion of the Lung CMap to profile additional lung cell-
types and additional drug compounds would significantly increase the sample size of 
these perturbations and allow us to make more definitive conclusions about the utility of 
organ-based gene expression profiling.     
These collective findings suggest, similar to previous work, that transcriptomics is an 
essential tool for informing exposure research and discovering significant gene-
environment interactions. Gene expression profiling can therefore be used to detail the 
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potential response of a compendium of chemical exposures including those that are either 
well-established or potential risk factors for chronic lung disease. 
 
5.3 Future Directions 
 Additional studies are warranted in order to provide further support for the utility 
of transcriptomics in exposure profiling. This body of work has focused primarily 
(though not exclusively) on in vitro chemical exposures in the airway epithelium. While 
transcriptomic profiling in vivo has been performed in TCIG users 2,7–9,43, to our 
knowledge our preliminary work profiling users of ECIGs is the first of its kind. 
Additional profiling of ECIG users and patients exposed to various drug treatments could 
demonstrate the physiological relevance of these findings and establish connections 
between these gene-environment interactions and lung disease. Furthermore, the 
impending results of our work exposing transformed airway epithelial cells to cigarette 
smoke constituents may help to illuminate the understanding of lung cancer progression. 
Lastly, further expansion of the Lung Connectivity Map will provide a genomic database 
of lung exposure in order to aid drug repurposing in the treatment of lung disease. 
Inclusion of the additional exposures presented in this body of work including TCIG 
smoke, TCIG constituents and ECIG aerosol would also further inform the potential 
health effects of these inhaled exposures and identify the components of traditional and 
electronic cigarettes that alter gene expression.   
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5.4 Overall Research Implications 
 This body of work serves as a novel application of human airway transcriptomics 
in assessing the exposure-response to three separate but equally complex chemical 
exposures. It further demonstrates the utility of transcriptomics in assessing potential 
health implications of novel and poorly understood environmental pollutants. These 
results demonstrate how gene-expression profiling can facilitate advancements in 
exposure research and elucidate the underlying molecular mechanisms that may 
precipitate lung disease. Inclusion of transcriptomic profiling in future exposure 
assessment studies will provide a methodology for characterizing the physiologic host 
response to chemical exposures of various sources and thereby inform harm reduction 
strategies aimed at mitigating the incidence of lung disease.   
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APPENDIX B 
 List of the 325 compounds used in the Lung CMap exposures in Chapter 4. 325 
compounds were randomly selected from the LINCS database based on availability. 
Compounds in bold, blue are positive controls. 	
7,8-Dihydro-L-Biopterin PKC-412 TPCA1 
Genipin Somatostatin Acetate IKK-3 Inhibitor IX 
Dilevalol GW501516 BIIB021 
Metaproterenol 
hemisulfate salt BAY-11-7082 PTACH 
Alfuzosin Gemcitabine Hydrochloride GDC-0941 
Cyclophosphamide 
monohydrate Obatoclax Mesylate Arctigenin 
GSK429286A 
Tenofovir Disoproxil 
Fumarate INCB018424 
(E/Z)-BCI hydrochloride PLX-4720 SB-202190 
chromomycin A3 MGCD0103(Mocetinostat) Elvitegravir 
Troglitazone Aprepitant(MK-0869) 
diacylglycerol kinase 
inhibitor 
HA14-1 Belinostat Glycocholic acid hydrate 
HU-211 Chenodeoxycholic acid Pemetrexed disodium 
5-Iodotubercidin H-8 mirin 
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GELDANAMYCIN U0126 SU6668 
thiostrepton Clofibric acid 
HBDDE (2,2',3,3',4,4'-
Hexahydroxy-1,1'-biphenyl-
6,6'-dimethanol dimethyl 
ether) 
erastin indirubin-3-oxime ABT-737 
Verrucarin?A, from 
Myrothecium sp. Gossypol from cotton seeds Amonafide 
LFM-A13 Sitagliptin MDV3100 
Fludarabine 
Phosphate(Fludara) AZD0530 LAQ824(NVP-LAQ824) 
Carbetocin 
Acetate(Duratocin) Lithocholic acid AZD6244 
rolipram 
Mitoxantrone 
dihydrochloride Tyrphostin AG 1295 
24(S)-Hydroxycholesterol RG-14620 YL54 
cyclazosin OM137 PI3-kinase inhibitor 
5b-Pregnan-3,20-dione Y-secretase Inhibitor XI SB-216763 
Mosapride citrate all-trans-Retinol VX-680(MK-0457) 
HC toxin Neurodazine Tyrphostin AG 879 
Methoprene acid lestaurtinib nelfinavir 
		
124 
TGX-221 Lavendustin A SU 11652 
iloprost Sorafenib Tosylate Vecuronium Bromide 
pioglitazone AT9283 Deguelin 
Withaferin A Farnesol 3-Methylcholanthrene 
Antimycin A from 
Streptomyces sp. 3a, 5a-Androstenol 24(S),25-Epoxycholesterol 
Tianeptine sodium salt KU-55933 Acitretin 
H-7 Warfarin PD-98059 
SQ 22,536 SC-514 Sphingosine 
2326-3228 Z-Guggulsterone Cilomilast(SB-207499) 
(Z)-guggulsterone 1a,25-Dihydroxyvitamin D3 ZSTK474 
Topotecan Hydrochloride Carbacyclin AS-604850 
Terreic acid H-89 AZD1152-HQPA 
Tetrahydrobiopterin Brivanib Gefitinib 
K-858 Ziprasidone hydrochloride Hh/Gli Antagonist, GANT58 
Evodiamine Hypericin Resistomycin 
fexofenadine 
hydrochloride Deforolimus 
Ispinesib mesilate(SB-
715992) 
DRB (5,6-Dichloro-1-b-
D-
ribofuranosylbenzimidazo Axitinib BI 2536 
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le) 
F1061-0166 syk inhibitor Ebelactone B microbial 
Ketoconazole GF 109203X Progesterone 
D609 Rifabutin Retinyl acetate 
Palmitoyl-DL-carnitine Cl Zibotentan (ZD4054) 3,5-Diiodo-L-thyronine 
Oxalomalic acid (sodium 
salt) CGP-53353 
HSP90 inhibitor, 
CCT018159 
Hyperforin BML-257 BIBW2992 
Celastrol Androstenedione Moxifloxacin 
KN-62 
HNMPA (Hydroxy-2-
naphthalenylmethylphospho
nic acid) Linezolid 
Ciglitizone CAY10577 N-Oleoylethanolamide 
Thalidomide AG-370 SB 431542 
Gestrinone Radicicol (monorden) AG-126 
4-Hydroxyretinoic acid 
Taurodeoxycholic acid 
sodium salt KU-0063794 
calmidazolium Ticrynafen GDC-0879 
Apigenin SU1498 1391-0741 
SP600125 2-Aminopurine MK-2206 
AZD2281(Olaparib) 9-cis-Retinoic acid Glycodeoxycholic acid 
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monohydrate 
LBH-589(Panobinostat) 
2,5-Dihydroxycinnamic acid 
methyl ester Erbstatin analog 
SU11274 ON-01910 ENMD-2076 
Tyrphostin 25 AZ-10417808 F1566-0341 
Rottlerin PU-H71 HMN-214 
Epirubicin 
Hydrocholoride (Ellence) Tamibarotene Staurosporine 
BIBR1532 Rivaroxaban Zosuquidar (LY335979) 
3,5-Diiodo-4-
hydroxyphenylpropionic 
acid Mifepristone BIBX-1382 
GSK1904529A Kenpaullone Masitinib (AB1010) 
B581 SB 525334 SNS-314 
CI-1040 (PD184352) Diindolylmethane N9-Isopropyl-olomoucine 
HA-1004 Paxilline BML-259 
3027-0077 
S-Farnesyl-L-cysteine 
methyl ester WZ4002 
tenovins Ochratoxin A ZM-447439 
5,8,11,14-
Eicosatetraynoic acid Tyrphostin 9 WZ3146 
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Ro 31-8220 S31-201 ZM 336372 
GSK1059615 Deoxycholic acid BI-78D3 
Nobiletin NVP-AUY922 IMD-0354 
AM-580 Tyrphostin 1 Pazopanib Hydrochloride 
Dexrazoxane 
Hydrochloride Daidzein APHA Compound 8 
CAY10470 Docetaxel(Taxotere) MLN8237 
Roscovitine(CYC202) CGP-57380 IC-87114 
GW 5074 Cholic acid HA-1077 
PHA-739358(Danusertib) Cortisone HNHA 
Tyrphostin AG 1288 AG-494 13-cis Retinoic acid 
Entecavir hydrate Voriconazole CP-724714 
Irinotecan AG-490 WYE-354 
Prostaglandin D2 Ki-8751 hydrate 25-Hydroxyvitamin D3 
H-9 PP1 reversine 
tunicamycin Floxuridine Xanthohumol 
Vinorelbine BX795 MS-275(Entinostat) 
Gemfibrozil Iloperidone(Fanapt) RO-3306 
Droxinostat Epothilone B(EPO906) 5-Aza-2?-deoxycytidine 
JNJ-7706621 BIBU 1361 dihydrochloride Enzastaurin 
Trimidox Tyrphostin 23 Acetyl-farnesyl-cysteine 
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ER-27319 TTNPB GW583340 dihydrochloride 
BEZ235 PD-0325901 
HDBA (2-Hydroxy-5-(2,5-
dihydroxybenzylamino)benz
oic acid) 
SL327 NVP-TAE684 
Pyrrolidinedithiocarbamate 
ammonium 
4,5-dianilinophthalimide CI-1033(Canertinib) Elesclomol 
Everolimus(RAD001) (E)-Capsaicin 6a-Fluorotestosterone 
IKK Inhibitor III BMS-
345541 Flupirtine maleate Olomoucine 
ABT-263 ellipticine IKK Inhibitor X 
GW0742 Cediranib PHA-665752 
NF-kB Activation 
Inhibitor II, JSH-23 ABT-888 Tyrphostin 47 
Pirarubicin Flavopiridol PD-173074 
JNJ 26854165 AG-825 SB 239063 
CHIR-258 CAY10585 Etodolac(Lodine) 
NPI-2358 withaferin-A radicicol 
Fluticasone calcitriol  	
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